[COMPANY_001] Research and Development  
KJX839 
Clinical Trial Protocol CKJX839A1US01 / [STUDY_ID_REMOVED]
A randomized, controlled, multicenter, open-label trial 
comparing a hospi[INVESTIGATOR_274724]-d ischarge ca re pathway 
involving ag gressive LDL-C management that includes 
inclisiran w ith u sual c are versus usual car e alone in 
patients with a recen t acute coronary syndrom e 
(VICTORION-I NCEPTION) 
Document type:  Clinical Trial Protocol  
EUDRACT number:  NA 
Version number:  04 (Amended Protocol)  (Clean)  
Clinical Trial Phase:  IIIb 
Release date:  20-Oct-2022
Property of [COMPANY_001]  
Confidential  
May not be used, divulged, published, or otherwise disclosed  
without the consent of [COMPANY_001]  
Clinical Trial Protocol Template Version 3.0 dated 31 -Jan-2020  
[COMPANY_001]  Confidential  Page 2 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Table of contents  
Table of contents ................................................................................................................. [ADDRESS_1179709] of abbreviations  ............................................................................................................ 7 
Glossary of terms  ............................................................................................................... 10 
Amendment 04 ......................................................................................................................... 13 
Amendment 03 ......................................................................................................................... 14 
Amendment 02 ......................................................................................................................... 16 
Amendment 01 ......................................................................................................................... 18 
1 Introduction ....................................................................................................................... 27 
1.1 Background ............................................................................................................ 27 
1.1.1 Atherosclerotic cardiovascular disease (ASCVD)  ................................ 27 
1.1.2 Mechanism of RNA Interference  .......................................................... 28 
1.1.3 Inclisiran  ................................................................................................ 28 
1.1.4 Non clinical studies ............................................................................... 29 
1.1.5 Clinical Studies  ..................................................................................... 29 
1.2 Purpose .................................................................................................................. 29 
2 Objectives, endpoints and estimands  ................................................................................. 30 
2.1 Primary estimands  ................................................................................................. 32 
2.2 Secondary estimands ............................................................................................. 33 
3 Study design ...................................................................................................................... 33 
4 Rationale ............................................................................................................................ 35 
4.1 Rationale for study design ..................................................................................... 35 
4.1.1 Rationale for choice of background therapy ......................................... 36 
4.2 Rationale for dose/regimen and duration of treatment .......................................... 37 
4.3 Rationale for choice of control drugs (comparator/placebo) or combination drugs ...................................................................................................................... 37
 
4.4 Purpose and timing of interim analyses/design adaptations .................................. 37 
4.5 Risks and benefits .................................................................................................. 37 
4.6 Rationale for Public Health Emergency mitigation procedures  ............................ 38 
5 Study Population ............................................................................................................... 38 
5.1 Inclusion criteria  .................................................................................................... 38 
5.2 Exclusion criteria  ................................................................................................... 39 
6 Treatment  ........................................................................................................................... 41 
6.1 Study treatment ...................................................................................................... 41 
[COMPANY_001]  Confidential  Page 3 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 6.1.1 Investigational and control drugs .......................................................... 41 
6.1.2 Additional study treatments .................................................................. 41 
6.1.3 Treatment arms/group  ........................................................................... 41 
6.1.4 Treatment duration  ................................................................................ 41 
6.2 Other treatment(s)  .................................................................................................. 41 
6.2.1 Concomitant therapy  ............................................................................. 41 
6.2.2 Prohibited medication  ........................................................................... 42 
6.3 Participant numbering, treatment assignment, randomization  .............................. 42 
6.3.1 Participant numbering  ........................................................................... 42 
6.3.2 Treatment assignment, randomization  .................................................. 43 
6.4 Treatment blinding  ................................................................................................ 43 
6.5 Dose escalation and dose modification .................................................................. 43 
6.5.1 Dose modifications ................................................................................ 43 
6.5.2 Follow-up for toxicities ......................................................................... 44 
6.6 Additional treatment guidance ............................................................................... 46 
6.6.1 Treatment compliance  ........................................................................... 46 
6.7 Preparation and dispensation  ................................................................................. 46 
6.7.1 Handling of study treatment and additional treatment .......................... 46 
6.7.2 Instruction for prescribing and taking study treatment ......................... 47 
7 Informed consent procedures ............................................................................................ 47 
8 Visit schedule and assessments  ......................................................................................... 48 
8.1 Screening  ............................................................................................................... 52 
8.1.1 Information to be collected on screening failures ................................. 52 
8.2 Participant demographics/other baseline characteristics  ....................................... 52 
8.3 Efficacy  .................................................................................................................. 52 
8.3.1 LDL -cholesterol  .................................................................................... 54 
8.3.2 Other lipoprotein measures  ................................................................... 54 
8.3.3 Appropriateness of efficacy assessments  .............................................. 54 
8.4 Safety  ..................................................................................................................... 55 
8.4.1 Laboratory evaluations  .......................................................................... 56 
8.4.2 Electrocardiogram (ECG) ..................................................................... 57 
8.4.3 Pregnancy and assessments of fertility  ................................................. 58 
8.4.4 Other safety evaluations  ........................................................................ 58 
8.4.5 Appropriateness of safety measurements  .............................................. 59 
8.5 Additional assessments  .......................................................................................... 59 
8.5.1 Clinical Outcome Assessments (COAs)  ............................................... 59 
[COMPANY_001]  Confidential  Page 4 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
   [ADDRESS_1179710]- study treatment  .......................................................... 62 
10 Safety monitoring and reporting  ........................................................................................ 63 
10.1 Definition of adverse events and reporting requirements ...................................... 63 
10.1.1 Adverse events ...................................................................................... 63 
10.1.2 Serious adverse events  .......................................................................... 64 
10.1.3 SAE reporting........................................................................................ 65 
10.1.4 Pregnancy reporting .............................................................................. 66 
10.1.5 Reporting of study treatment errors including misuse/abuse ................ 66 
10.2 Additional Safety Monitoring  ................................................................................ 67 
10.2.1 Liver safety monitoring  ......................................................................... 67 
10.2.2 Renal safety monitoring  ........................................................................ 68 
10.2.3 Steering Committee  ............................................................................... 68 
11 Data Collection and Database management  ...................................................................... 68 
11.1 Data collection  ....................................................................................................... 68 
11.2 Database management and quality control ............................................................ 69 
11.3 Site monitoring  ...................................................................................................... 69 
12 Data analysis and statistical methods  ................................................................................ 70 
12.1 Analysis sets .......................................................................................................... 70 
12.2 Participant demographics and other baseline characteristics  ................................. 71 
12.3 Treatments  ............................................................................................................. 71 
12.4 Analysis supporting primary objectives ................................................................ 71 
12.4.1 Definition of primary endpoints  ............................................................ 71 
12.4.2 Statistical model, hypothesis, and method of analysis .......................... 71 
12.4.3 Handling of intercurrent events of primary estimand  ........................... 73 
12.4.4 Handling of missing values not related to intercurrent event  ............... 73 
12.4.5 Sensitivity analyses  ............................................................................... 73 
12.4.6 Supplementary analysis ......................................................................... 74 

[COMPANY_001]  Confidential  Page 5 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 12.4.7 Supportive analyses  ............................................................................... 74 
12.5 Analysis supporting secondary objectives ............................................................. 75 
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s) .................................... 75 
12.5.2 Safety endpoints .................................................................................... 76 
12.5.3 Pharmacokinetics  .................................................................................. 77 
12.5.4 DNA  ...................................................................................................... 77 
12.5.5 Biomarkers  ............................................................................................ 77 
12.5.6 PK/PD relationships  .............................................................................. 77 
  77 
12.6 Analysis of exploratory endpoints  ......................................................................... 77 
12.7 Interim analyses  ..................................................................................................... 78 
12.8 Sample size calculation .......................................................................................... 78 
12.8.1 Primary endpoint(s)  ............................................................................... 78 
12.8.2 Secondary endpoint(s) ........................................................................... 79 
13 Ethical considerations and administrative procedures  ...................................................... 79 
13.1 Regulatory and ethical compliance ........................................................................ 79 
13.2 Responsibilities of the investigator and IRB/IEC  .................................................. 79 
13.3 Publication of study protocol and results............................................................... 80 
13.4 Quality Control and Quality Assurance  ................................................................. 80 
14 Protocol adherence  ............................................................................................................ 80 
14.1 Protocol amendments ............................................................................................. 81 
15 References  ......................................................................................................................... 82 
16 Appendices ........................................................................................................................ 85 
16.1 Appendix 1: Clinically notable laboratory values and vital signs ......................... 85 
16.2 Appendix 2: Liver event and laboratory trigger definitions & follow-up 
requirements .......................................................................................................... 86 
16.3 Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow-up ...... 89 
16.4 Appendix 4: Sampson Criteria for Diagnosing Anaphylaxis ................................ [ADDRESS_1179711] of tables  
Table 2 -1 Objectives and related endpoints .......................................................... 30 
Table 6 -1 Investigational and control drug ............................................................ 41 
Table 6 -2 Prohibited medication  ........................................................................... 42 

[COMPANY_001]  Confidential  Page 6 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Table 6 -3  Guidance on specific clinical and diagnostic assessments which can be performed to rule out possible alternative causes of observed LFT abnormalities ................................................................. 45
 
Table 6 -4 Dose and treatment schedule  ................................................................. 47 
Table 8 -1 Assessment Schedule  ............................................................................ 50 
Table 8 -2 Safety Assessment  ................................................................................. 55 
Table 8 -3 Clinical Laboratory Assessments  .......................................................... 57 
Table 10-1 Guidance for capturing the study treatment errors including misuse/abuse ......................................................................................... 67
 
Table 12-1 Sample size calculations for percent change from baseline in LDL -
C ............................................................................................................ 78 
Table 12-2 Sample size calculations for achieving LDL -C < 70 mg/dL ................ [ADDRESS_1179712] of figures  
Figure 3-1 Study Design ......................................................................................... 34 
 
[COMPANY_001]  Confidential  Page 7 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 List of abbreviations  
ACS Acute coronary syndrome   
AE Adverse Event  
ALP Alkaline Phosphatase  
ALT Alanine Aminotransferase  
ASCVD  Atherosclerotic cardiovascular disease  
AST Aspartate Aminotransferase  
BMI Body Mass Index  
BUN  Blood Urea Nitrogen  
CHD  Coronary heart disease  
CK Creatinine Kinase  
COA  Clinical Outcome Assessment  
CQA  Clinical Quality Assurance  
CRF Case Report/Record Form (paper or electronic)  
CRO  Contract Research Organization  
CV Cardiovascular  
DBP Diastolic Blood Pressure  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
eGFR  estimated Glomerular Filtration Rate  
EHR  Electronic Health Record  
FDA Food and Drug Administration  
GalNAc  N-acetylgalactosamine  
GCP  Good Clinical Practice  
GGT  Gamma -glutamyl transferase  
GLDH  Glutamate Dehydrogenase  
GPP  Good Pharmaceopi[INVESTIGATOR_848458]  B Core  Antibody  
HBsAb  Hepatitis  B Surface  Antibody  
HBsAg  Hepatitis B surface antigen  
HBV Hepatitis B Virus  
hCG Human Chorionic Gonadotropin  
HCV  Hepatitis C Virus  
HDL-C High Density Lipoprotein Cholesterol  
HEOR  Health Economics & Outcomes Research  
HIV Human immunodeficiency virus  
HRQoL  Health -Related Quality of Life  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council for Harmonization of Technical Requirements for Pharmaceuticals 
for Human Use  
IEC Independent Ethics Committee  
[COMPANY_001]  Confidential  Page 8 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 IN Investigator Notification  
INR International Normalized Ratio  
IRB Institutional Review Board  
IRT Interactive Response Technology  
ISR Injection Site Reaction  
IUD intrauterine device   
IUS intrauterine system  
LDH lactate dehydrogenase  
LDL-C low density lipoprotein cholesterol  
LFT Liver function test  
LLN lower limit of normal  
LNP lipid nanoparticle  
Lp(a)  Lipoprotein(a)   
MACE  Major adverse cardiovascular events   
  
MedDRA  Medical dictionary for regulatory activities  
mg milligram(s)  
MI Myocardial Infarction  
mL milliliter(s)  
MMRM  Mixed -effects model repeated measures   
mRNA  Messenger RNA   
No. Number  
NOACs  novel or non -Vitamin K oral anticoagulants  
NYHA  [LOCATION_001] Heart Association   
PD Pharmacodynamic(s)  
PFS Pre-Filled Syringe  
PK Pharmacokinetic(s)  
PRO  Patient Reported Outcomes  
PT prothrombin time  
QMS  Quality Management System  
RBC  red blood cell(s)  
RISC  RNA -Induced Silencing Complex   
RNAi  Ribonucleic acid interference   
RU Resource Utilization  
s.c. subcutaneous  
SAE Serious Adverse Event  
SBP Systolic Blood Pressure  
sCR serum creatinine  
SGOT  Serum Glutamic Oxaloacetic Transaminase  
SGPT  Serum Glutamic Pyruvic Transaminase  
siRNA  small interfering ribonucleic acid  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  

[COMPANY_001]  Confidential  Page 9 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 TBL Total Bilirubin  
  
ULN upper limit of normal  
VLDL  Very-Low-Density Lipoprotein  
WBC  white blood cell(s)  
WHO  World Health Organization  
WoC  Withdrawal of Consent  

[COMPANY_001]  Confidential  Page 10 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Glossary of terms  
Additional 
treatment  Medicinal products that may be used during the clinical trial as described in 
the protocol, but not as an investigational medicinal product (e.g. any 
background therapy)  
Assessment  A procedure used to generate data required by [CONTACT_6551]  A biological specimen including, for example, blood (plasma, serum), saliva, 
tissue, urine, stool, etc. taken from a study participant  
Clinical Outcome 
Assessment (COA)  A measure that describes or reflects how a participant feels, functions, or 
survives  
Clinical Trial Team  A group of people responsible for the planning, execution and reporting of all clinical trial activities. Examples of team members include the Study Lead, 
Medical Monitor, Trial Statistician etc.  
Coded Data  Personal Data which has been de -identified by [CONTACT_131323] a code.  
Cohort  A specific group of participants fulfilling certain criteria and generally treated 
at the same time  
Control drug  A study drug (active or placebo) used as a comparator to reduce assessment 
bias, preserve blinding of investigational drug, assess internal study validity, 
and/or evaluate comparative effects of the investigational drug  
Discontinuation from study  Point/time when the participant permanently stops receiving the study treatment and further protocol required assessments or follow -up, for any 
reason. No specific request is made to stop the use of their samples or data.  
Discontinuation 
from study 
treatment  Point/time when the participant permanently stops receiving the study 
treatment for any reason (prior to the planned completion of study drug 
administration, if any). Participant agrees to the other protocol required 
assessments including follow- up. No specific request is made to stop the use 
of their samples or data.  
Dosage Dose of the study treatment given to the participant in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)  
Electronic Data 
Capture (EDC)  Electronic data capture (EDC) is the electronic acquisition of clinical study 
data using data collection systems, such as Web -based applications, 
interactive voice response systems and clinical laboratory interfaces. EDC 
includes the use of Electronic Case Report Forms (eCRFs) which are used to 
capture data transcribed from paper source forms used at the point of care  
End of the clinical 
trial The end of the clinical trial is defined as the last visit of the last participant or 
at a later point in time as defined by [CONTACT_301986]/time of participant entry into the study at which informed consent must 
be obtained  
eSource (DDE)  Electronic source (eSource) Direct Data Entry (DDE) refers to the capture of 
clinical study data electronically, at the point of care. eSource 
Platform/Applications combines source documents and case report forms 
(eCRFs) into one application, allowing for the real time collection of clinical 
trial information to sponsors and other oversight authorities, as appropriate  
[COMPANY_001]  Confidential  Page 11 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Estimand   A precise description of the treatment effect reflecting the clinical question posed by [CONTACT_6553]. It summarizes at a population-level what the outcomes would be in the same patients under different treatment conditions 
being compared. Attributes  of an estimand include the population, variable (or 
endpoint) and treatment of interest, as well as the specification of how the 
remaining intercurrent events are addressed and a population- level summary 
for the variable.  
Healthy volunteer  A person with no known significant health problems who volunteers to be a 
study participant  
Intercurrent events  Events occurring after treatment initiation that affect either the interpretation 
or the existence of the measurements associated with the clinical question of 
interest.  
Investigational 
drug/ treatment  The drug whose properties are being tested in the study  
Medication number  A unique identifier on the label of medication kits  
Mis-randomized 
participants  Mis-randomized participants are those who were not qualified for 
randomization and who did not take study treatment, but have been 
inadvertently randomized into the study  
Off-site Describes trial activities that are performed at remote location by [CONTACT_106623] -site 
healthcare professional, such as procedures performed at the participant's 
home.  
Off-site healthcare 
Professional (OHP)  A qualified healthcare professional, such as a nurse, phlebotomist or physician, who performs certain protocol procedures for the participant in an 
off-site location such as a participant's home.  
Other treatment  Treatment that may be needed/allowed during the conduct of the study (i.e. 
concomitant or rescue therapy)  
Part  A sub -division of a study used to evaluate specific objectives or contain 
different populations. For example, one study could contain a single dose part 
and a multiple dose part, or a part in participants with established disease and 
in those with a newly diagnosed disease  
Participant  A trial participant (can be a healthy volunteer or a patient)  
Participant number  A unique number assigned to each participant upon signing the informed 
consent. This number is the definitive, unique identifier for the participant and 
should be used to identify the participant throughout the study for all data 
collected, sample labels, etc. 
Patient -Reported 
Outcome (PRO)  A measurement based on a report that comes directly from the patient about 
the status of a participant's health condition without amendment or 
interpretation of the patient's report by a clinician or anyone else  
Period  The subdivisions of the trial design (e.g., Screening, Treatment, Follow -up) 
which are described in the Protocol. Periods define the study phases and will 
be used in clinical trial database setup and eventually in analysis  
Personal data Participant information collected by [CONTACT_157058]. This data includes 
participant identifier information, study information and biological samples.  
Premature 
participant 
withdrawal  Point/time when the participant exits from the study prior to the planned 
completion of all study drug administration and/or assessments; at this time 
all study drug administration is discontinued, and no further assessments are 
planned  
[COMPANY_001]  Confidential  Page 12 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Randomization The process of assigning trial participants to investigational drug or control/comparator drug using an element of chance to determine the 
assignments in order to reduce bias.  
Randomization 
number  A unique identifier assigned to each randomized participant  
Re-screening  If a participant fails the initial screening and is considered as a Screen Failure, he/she can be invited once for a new Screening visit after medical judgment 
and as specified by [CONTACT_30763] a location that is not the investigative site where the investigator will conduct the trial, but is for 
example a home or another appropriate location  
Screen Failure  A participant who did not meet one or more criteria that were required for 
participation in the study  
Source 
Data/Document  Source data refers to the initial record, document, or primary location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet, or even hard -coded data, such as paper or eSource  
Start of the clinical 
trial The start of the clinical trial is defined as the signature [CONTACT_30832] [CONTACT_848488]; includes investigational 
drug(s), control(s) or background therapy  
Study treatment 
discontinuation When the participant permanently stops taking any of the study drug(s) prior to the defined study treatment completion date (if any) for any reason; may or 
may not also be the point/time of study discontinuation  
Tele-visit Procedures or communications conducted using technology such as 
telephone or videoconference, whereby [CONTACT_131327].  
Treatment 
arm/group  A treatment arm/group defines the dose and regimen or the combination and 
may consist of [ADDRESS_1179713], which might or might not be the same 
as the study treatment.  
Variable (or 
endpoint)  The variable (or endpoint) to be obtained for each participant that is required to address the clinical question.  The specification of the variable might include 
whether the participant experiences an intercurrent event.  
Withdrawal of 
study consent 
(WoC)  Withdrawal of consent from the study occurs only when a participant does not want to participate in the study any longer and does not allow any further 
collection of personal data   
[COMPANY_001]  Confidential  Page 13 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Amendment 04  
Amendment rationale  
The purpose of the clinical study amendment is to clarify the use of inclisiran, which is now 
commercially available as LEQVIO®. Exclusion criteria #[ADDRESS_1179714] the same. The number of sites was increased from 40 to up to approximately 130. 
Changes to the protocol  
• Section 3 Study Design:  Added “Commercially available inclisiran  may be used for 
appropriate patients in the usual care arm at the sole discretion of the treating physician, 
without any influence from the PI.” Deleted “If and when…treating physician” 
• Section 5 Study Population: The number of sites was increased from 40 to up to 
approximately 130 
• Section 5.2  
o Exclusion criteria #15: Added “Treatment with monoclonal antibodies directed towards 
PCSK9 or inclisiran within 90 days of screening.”  
o Exclusion criteria #11: Added “Approved vaccines or vaccines used under Emergency Use Authorization   should not be considered part of this exclusion criteria. Patients can receive 
COVID vaccines during inclisiran trials.  
While use of COVID anti -viral therapi[INVESTIGATOR_848459], they would not be considered as criteria for trial termination/discontinuation.  
[COMPANY_001]  Confidential  Page 14 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Amendment 03  
Amendment rationale  
The purpose of the clinical study amendment is to clarify the understanding of what is meant 
by [CONTACT_848489][INVESTIGATOR_848460] (ACS).  The term “hospi[INVESTIGATOR_059]” applies to patients who are either admitted to the hospi[INVESTIGATOR_189294] -patient or 
in an out-patient setting (i.e., not requiring admission for an overnight hospi[INVESTIGATOR_4408]).   
Some of the inclusion and exclusion criteria have been modified.  The criteria for glomerular 
filtration rate has been reduced from a calculated value greater than 30 ml/min to a value greater than 20 ml/min.  The exclusion criteria for heart failure (HF) has been changed from class III or IV HF to now only excluding participants with class IIIb or IV HF or a left ventricular ejection fraction less than 25%.  The exclusion criteria for The protocol amendment has also removed the requirement for participants  to be randomized within [ADDRESS_1179715] 30 days following screening to randomize a participant into the trial.  
Changes to the protocol  
• Protocol Summary  
o Purpose and rationale:   added “… with a previous hospi[INVESTIGATOR_059] (in- patient/out -
patient) for an ACS …”  
o Primary Objective:  added “… in participants with a recent hospi[INVESTIGATOR_059] (in -
patient/out- patient) for an ACS ...”  
o Study population:   added “… with a recent hospi[INVESTIGATOR_059] (in -patient/out-
patient) for an ACS …”  
o Inclusion criteria #2: Added “Recent ACS (in -patient/out- patient) within 5 
weeks of screening), …”  
o Inclusion criteria #3: Added “Serum LDL -C ≥70 mg/dL or non- HDL ≥100 
mg/dL” 
o Inclusion criteria #5: Modified “calculated glomerular filtration rate >20 ml/min …” 
o Inclusion criteria #7: Added “… following hospi[INVESTIGATOR_059] (in -patient/out-
patient) for an ACS.”  
o Exclusion criteria #1: Modified “[LOCATION_001] Heart Association (NYHA) class IIIb …” and  “… last known left ventricular ejection fraction <25%.”  
o Exclusion criteria #6: Modified “Treatment with monoclonal antibodies directed towards PCSK9 within 90 days of screening.” 
• Section 1.1  Background:  added “… with inclisiran in participants with a recent 
hospi[INVESTIGATOR_059] (in -patient/out- patient) for an ACS …”  
[COMPANY_001]  Confidential  Page 15 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 • Section 1.2 Purpose:  added “a recent ACS (in -patient/out- patient) within 5 weeks of 
screening.” and added “… initiation of inclisiran in participants with a recent hospi[INVESTIGATOR_059] (in -patient/out- patient) for an ACS …”  
• Table 2 -1  under Primary objectives:  added “initiation of inclisiran in participants with 
a recent hospi[INVESTIGATOR_059] (in -patient/out- patient) …”  
• Section 2.1  Primary estimands:  removed “within 5 weeks” and added “… 
implementation pathway in participants following a recent ACS, …”  
• Section 3  Study Design:   deleted “and randomization” to now state: “Screening of 
participants must take place within 5 weeks after discharge.”  
• Section 4.1 Recruitment:  added “… recently hospi[INVESTIGATOR_848461] (in-patient/out-
patient), …”  
• Section 5 added “… with a recent hospi[INVESTIGATOR_059] (in-patient/out- patient) for an ACS 
(within 5 weeks) …” 
 
• Section 5.1  
o Inclusion criteria #2: Added “Recent ACS (in-patient/out- patient) within 5 
weeks of screening, …” 
o Inclusion criteria #3: Added “Serum LDL -C ≥70 mg/dL or non- HDL ≥100 
mg/dL” 
o Inclusion criteria #5: Modified “…calculated glomerular filtration rate >20 ml/min …”  
o Inclusion criteria #7: Removed “discharged” and added “in -patient/outpatient” 
to “Participants are required to be on statin therapy, or have documented statin intolerance, as determined by [CONTACT_093], following hospi[INVESTIGATOR_059] (in-patient/outpatient) …”. 
 
• Section 5.2  
o Exclusion criteria #3: Modified “[LOCATION_001] Heart Association (NYHA) class 
IIIb …” and  “… last known left ventricular ejection fraction <25%.”  
o Exclusion criteria #15: Modified “Treatment with monoclonal antibodies directed towards PCSK9 within 90 days of screening.” 
[COMPANY_001]  Confidential  Page 16 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Amendment [ADDRESS_1179716] and obtain 
consent from the female partner of any male participant when the female partner becomes pregnant during the study in order to obtain pregnancy outco me information.  
This protocol amendment, finalized prior to study start, will be the initial protocol version submitted to regulatory authorities, including the FDA, and Site IRBs for study approval. 
Changes to the protocol  
• Updated list of abbreviations to include Injection Site Reaction  
• Protocol Summary  
o Data Analysis section updated efficacy variables being analyzed  
• Section 3 added language, “if and when inclisiran becomes commercially available”  
• Section 6.5.1 removed “not applicable” and provided guidance with respect to drug 
interruptions and/or drug discontinuation 
• Section 6.5.2 
o Removed not applicable  
o Added Section [IP_ADDRESS] follow up on potential drug- induced liver injury (DILI) 
cases  
• Section [IP_ADDRESS] removed language that participants will be asked to return all unused 
study medication  
• Section 7 removed pregnant partner information 
• Section 8  
o Included language for required 8 hour fasting prior to laboratory evaluations 
o Included language that blood donations are prohibited during study participation  
• Table 8 -1 
o Added “Medical History: Statin Intolerance”  
o Added footer for “Weight” to be captured at visits 3, 4 and 5 
o Updated “Pulse Rate” and “Blood Pressure” to be captured at visits 3 and 4  
o Added “prior or” to concomitant medications   
o Added “Surgical / Medical procedures”  
[COMPANY_001]  Confidential  Page 17 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 o Added “Injection Site Reaction Assessment”  
o Updated footer numbers   
o Provided clarification of biobanking collection at Visits 2 -5  
• Section 8.2 removed “date of birth” 
• Table 8 -3 removed “Lactate” from full serum chemistry  
• Section 8.4.4 added “Injection site reactions” and “Hyperglycemia -related events” 
information  
•   
• Section 8.5.3  
o Added analysis of proteins.  
o Updated language to indicate all measures of Lp(a) and hsCRP are blinded to 
participants and staff and to allow for any lab measures from the biobank 
samples to be analyzed during or after study close  
• Section 10.1.[ADDRESS_1179717] “pregnancies” at the start of the paragraph and 
pregnant partner information   
• Section 10.2  removed “not applicable”  
• Section 10.2.[ADDRESS_1179718] for unexplained increases in transaminases or total 
bilirubin, as well as instructions on follow -up, as this is now captured in section [IP_ADDRESS], 
Appendix 2 and in the remainder of the paragraph 
• Section 11.[ADDRESS_1179719] EHR Data Capture 
and Linked Pharmacy & Medical Claims Data information  
• Section 12.5.1 updated efficacy variables being analyzed 
 

[COMPANY_001]  Confidential  Page 18 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Amendment [ADDRESS_1179720] been updated to remove the Belief about Medication Questionnaire (BMQ).   
The protocol updated the sections with respect to the capture of EHR and claims data into the 
database to state that it may not be possible in all patients.  
The protocol was also updated according to the most recent version (4.0) of the clinical trial protocol template, issued on 15- Feb-2021.   
Changes to the protocol have also been made to align with another ongoing Phase IIIb clinical study with inclisiran (KJX839A1US02). Other changes to the protocol included the addition of a study name [CONTACT_848505]. 
Changes to the protocol  
• Title page study name “VICTORION -INCEPTION” added to title.  
• List of abbreviations were updated to include EHR, GPP, HBcAb, HBsAb, hCG, HDL -
C, VLDL,  
• Glossary of terms were updated to include Clinical Outcomes Assessment (COA), 
Clinical Trial Team, Coded Data, Discontinuation from study, Discontinuation from study treatment, off -site, off -site healthcare professional (OHP), Patient-Reported 
Outcomes (PR O), Randomization, Re -screening, Remote and Tele- visit.  
• Glossary of terms were updated to remove cycles and run- in failure  
• Protocol Summary  
o Full title “VICTORION -INCEPTION” was added  
o Clinical Phase was updated to Phase IIIb  
o Study type was updated to interventional 
o Key Exclusion criteria was added.  
 Recurrent ACS event within 2 weeks prior to randomization.  
 Coronary angiography and revascularization procedure (percutaneous coronary intervention (PCI) or coronary artery by[CONTACT_15806] (CABG) 

[COMPANY_001]  Confidential  Page 22 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 new studies. No analysis will be performed using post -baseline data. Thus, there is no 
need to adjust the level of significance for such interim analysis of baseline data.”  
• Section 12.8.1 added “ trial since changes in lipid -lowering therapy are allowed in both 
treatment groups.”  
• Section 15 updated references  
  
Other typographical corrections were also included.  
Changes to specific sections of the protocol are shown in the track changes version of the protocol using strike through red font for deletions and red underlined for insertions.  
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board (IRBs)/Independent Ethics Committee (IECs) and Health Authorities. The changes described in this amended protocol require IRB/IEC and Health Authority approval according to loca l 
regulations prior to implementation.  
  

[COMPANY_001]  Confidential  Page 23 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Protocol summary 
Protocol 
number  CKJX839A1US01  
Full Title  A randomized, controlled, multicenter, open-label trial comparing a hospi[INVESTIGATOR_274724] -
discharge care pathway involving aggressive LDL- C management that includes 
inclisiran with usual care versus usual care alone in patients with a recent acute 
coronary syndrom e(VICTORION -INCEPTION)  
Brief title  Management of LDL- cholesterol with inclisiran + usual care compared to usual 
care alone in participants with a recent acute coronary syndrome  
Sponsor and 
Clinical Phase  [COMPANY_001], Phase IIIb  
Investigation 
type Drug  
Study type  Interventional clinical trial  
Purpose and rationale  The purpose of this study is to study the effectiveness of implementation of a systematic LDL -C management pathway including treatment with inclisiran in 
participants who have experienced a recent acute coronary syndrome (ACS) 
and have an increased LDL- cholesterol (≥70 mg/dL) despi[INVESTIGATOR_848462] a 
statin drug.  
In this context, we aim to assess the LDL- C lowering effects of aggressive LDL- C 
management with inclisiran on top of usual care in patients with a previous 
hospi[INVESTIGATOR_059] (in -patient/out -patient) for an ACS compared to patients receiving 
usual, care with out inclisiran.   
Primary Objective(s)  The primary objective of this study is to assess the effect on LDL -C of 
implementation of an LDL- C management care pathway that includes initiation 
of inclisiran on top of usual care in participants with a recent hospi[INVESTIGATOR_059] (in -
patient/out -patient) fo r an ACS with LDL- C ≥70 mg/dL despi[INVESTIGATOR_848463] 330.   
Secondary 
Objectives  The secondary objectives in this study include the following:   
To assess (1) the absolute change from baseline in LDL- C level at Day 330, and 
(2) average of absolute and percent changes from baseline in LDL- C levels to 
each post -baseline visit, in the inclisiran + usual care  group compared to usual 
care group at Day 3 30  
To assess the proportion of participants reaching pre-specified LDL- C targets in 
the inclisiran + usual care group compared to usual care group at Day 330  
To assess plasma lipoproteins and triglycerides in the inclisiran + usual 
care group compared to usual care group at Day 330  
To assess changes in and adherence to background lipid-lowering therapy in the inclisiran + usual care  group compared to usual care group at Day 330  
To assess overall safety and tolerability of inclisiran  
Study design The study design will be a randomized, parallel -group, open- label, controlled, 
multicenter study comparing an LDL- C management strategy including inclisiran 
with usual care.  
Study 
population  Male or female participant’s ≥18 years of age with a recent hospi[INVESTIGATOR_059] (in-
patient/out -patient) for an ACS and elevated LDL -C (≥70 mg/dL) despi[INVESTIGATOR_848464] 24 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 treated with statin therapy by [CONTACT_848490]. We plan to 
randomize approximately [ADDRESS_1179721] meet all of the following 
criteria:  
1. Males and females ≥18 years of age  
2. Recent ACS (in-patient/out -patient) within 5 weeks of screening, defined as:  
Ischemic symptoms with unstable pattern, occurring at rest or minimal 
exertion within [ADDRESS_1179722] one of the following:  
a. Elevated cardiac biomarkers (cardiac troponin (cTn ) or the MB fraction of creatinine kinase (CKMB)) with at least one value above the 99th 
percentile of the upper reference limit (URL) or defined by [CONTACT_848491] -off values  OR 
b. Resting ECG changes consistent with ischemia or infarction AND additional evidence of obstructive coronary disease  
3. Serum LDL -C ≥70 mg/dL or non -HDL ≥100 mg/dL  
4. Fasting triglycerides <4.52 mmol/L (<400 mg/dL) at screening  
5. Calculated glomerular filtration rate >20 mL/min by [CONTACT_131328] (eGFR)  
6. Participants must be willing and able to give informed consent before 
initiation of any study related procedures and willing to comply with all required study procedures  
7. Participants are required to be on statin therapy, or have documented statin 
intolerance, as determined by [CONTACT_093], following hospi[INVESTIGATOR_059] (in-
patient/out -patient) for an ACS. Statin intolerant patients are eligible if they 
had intolerable side effects on at least [ADDRESS_1179723] dose.  
Key Exclusion criteria  • [LOCATION_001] Heart Association (NYHA) class IIIb or IV heart failure or last known left ventricular ejection fraction <25%.  
• Significant cardiac arrhythmia within 3 months prior to randomization that is not controlled by [CONTACT_131329].  
• Severe concomitant non- cardiovascular disease that carries the risk of 
reducing life expectancy to less than 2 years.  
• Treatment with other investigational products or devices within 30 days or five half˗lives of the screening visit, whichever is longer.  
• Planned use of other investigational products or devices during the course of the study.  
• Treatment with monoclonal antibodies directed towards PCSK9 or with inclisiran within 90 days of screening.
  
• Recurrent ACS event within 2 weeks prior to randomization.  
• Coronary angiography and revascularization procedure (percutaneous coronary intervention (PCI) or coronary artery by[CONTACT_15806] (CABG) 
surgery) performed within 2 weeks prior to the randomization visit or 
planned after randomization.   
• Approved vaccines or vaccines used under Emergency Use Authorization  should not be considered part of this exclusion criteria. Patients can receive COVID vaccines during inclisiran trials.  
While use of COVID anti -viral therapi[INVESTIGATOR_848465] 26 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 2. Average percent change from baseline in LDL -C levels to each post -
baseline visit  
3. Average absolute change from baseline in LDL- C levels to each post -
baseline visit  
4. Achieving LDL- C < 100 mg/dL (yes, no) (among the subset of participants 
with LDL- C ≥ 100 mg/dL at baseline)  
5. Achieving ≥ 50% reduction from baseline in LDL- C (yes, no)  
6. Achieving LDL- C < 55 mg/dL (yes, no)  
7. Percent change from baseline in apoB  
8. Absolute change from baseline in apoB  
9. Percent change from baseline in VLDL  
10. Absolute change from baseline in VLDL  
11. Percent change from baseline in non -HDL-C 
12. Absolute change from baseline in non -HDL-C 
13. Percent change from baseline in total cholesterol  
14. Absolute change from baseline in total cholesterol  
15. Percent change from baseline in Lp(a)  
16. Absolute change from baseline in Lp(a)  
17. Percent change from baseline in HDL-C 
18. Absolute change from baseline in HDL -C 
19. Percent change from baseline in triglycerides  
20. Absolute change from baseline in triglycerides  
21. Intensity of lipid -lowering therapy (decrease in dose, no change in dose, 
increase in dose)  
22. Proportion of days covered (total number of days on either statin, ezetimibe, 
or PCSK9 inhibiting monoclonal antibody  therapi[INVESTIGATOR_848466])  
23. Discontinuation of statin therapy (i.e., no statin use ≥ 30 days before the 
end-of-study visit) (yes, no)  
Analyses of secondary efficacy variables 1 and 7 - 20 will be similar to the primary 
analysis of primary efficacy variable 1 (using MMRM, but with a two- sided 95% 
confidence interval for the treatment difference).  
Secondary efficacy variables 2, 3, and [ADDRESS_1179724] -baseline visit using 
a proportional odds model with treatment and baseline LDL- C as explanatory 
variables.  
Key words  Hyperlipi[INVESTIGATOR_035], Acute Coronary Syndrome (ACS), Secondary Cardiovascular Prevention, Atherosclerotic Cardiovascular Disease (ASCVD), 
Hypercholesterolemia, Lipid lowering therapi[INVESTIGATOR_848467] 27 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 1 Introduction  
1.1 Background 
Inclisiran is a novel synthetic small interfering ribonucleic acid (siRNA) therapeutic for subcutaneous (SC) injection for the treatment of hypercholesterolemia. Inclisiran has been shown to lower low density lipoprotein cholesterol  (LDL -C) by 50% or more in patients with 
stable established atherosclerotic cardiovascular disease (ASCVD) who are treated with maximally tolerated statin therapy ( Ray et al 2020). It is not known, however, if participants 
who have had a recent acute coronary syndrome (ACS) would have similar effects on LDL -C, 
with respect to the use of inclisiran, since these patients were excluded from participation in the Phase III registration  trials.  
The purpose of this trial is to assess the LDL -C lowering effects of aggressive LDL -C 
management with inclisiran in participants with a recent hospi[INVESTIGATOR_059] (in -patient/out- patient) 
for an ACS and have an LDL- C ≥70 mg/dL while receiving statin therapy. 
This study will be conducted in compliance with Good Clinical Practices (GCP) and  Good 
Pharmacoepi[INVESTIGATOR_61272] (GPP),  including the Declaration of Helsinki and all 
applicable regulatory requirements.  
1.1.1 Atherosclerotic cardiovascular disease (ASCVD)  
Patients who have experienced an ASCVD event, including patients with coronary heart disease (CHD), are at a higher risk of having another cardiovascular (CV) event ( Grundy et  al 2019). 
Lowering of low density lipoprotein cholesterol (LDL -C) is one of the most important treatment 
strategies to help prevent a recurrent CV event ( Baigent et  al 2010).  CHD patients, including 
those who experienced an ACS, should receive long- term intensive lipid lowering therapy 
starting with a hydroxymethylglutaryl -coenzyme A (HMG -CoA)  reductase inhibitor (statin) as 
reductions in LDL -C have demonstrated significant reductions in CV morbidity and mortality 
both in patients with stable ASCVD and in those with a recent ACS ( Mills  et al 2011; 
Cannon et  al 2004; Collins et  al 2016 ). 
The most recent treatment guidelines by [CONTACT_848492] a high intensity statin (atorvastatin (40 mg) or rosuvastatin (20 mg)) as early as possible (1 -4 days) after the diagnosi s of ACS has been 
made with a goal of achieving at least 50% reduction in LDL -C (Grundy et  al 2019 ). In those 
same patients whose LDL -C remains ≥70 mg/dL, use of other non- statin therapi[INVESTIGATOR_848468]- C.  
A more aggressive reduction in LDL -C in ACS patients was associated with further reductions 
in CV morbidity and mortality but data is limited when evaluating the efficacy of various lipid lowering therapi[INVESTIGATOR_848469] ( Wilson  et al 2019). Aggressive LDL -C targets 
are not easy to achieve in patients following an ACS with statin therapy alone (Rosenblit 2019; Koskinas et  al 2019 ). The risk of recurrent CV events is lower in patients 
receiving more intensive LDL -C lowering with the addition of non- statin therapi[INVESTIGATOR_014] (e.g., 
ezetimibe and PCSK9 -inhibition) in patients already on maximally tolerated statin therapy but 
requires a struct ured step -wise approach to achieve target goals 
(Cannon et  al 2015; Sabatine et  al 2017; Schwartz et  al 2018). Reasons for poor LDL -C 
[COMPANY_001]  Confidential  Page 28 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 control rates in ACS patients can be attributed to multiple factors including: the inability to titrate statins to higher doses due to tolerability issues at higher doses, lack of a therapeutic target or goal to achieve for LDL -C with no regular assessment  of LDL -C levels, and poor 
adherence to lipid lowering therapy ( Lambert -Kerzner  et al 2015 ; Anderson et  al 2018). 
Employing a guideline directed medical therapy plan in ACS patients with a LDL -C goal of 
<70 mg/dL can be achieved. However, it requires the use of high- intensity statins at maximally 
tolerated doses and the use of add -on non- statin therapi[INVESTIGATOR_014] (Cannon et  al 2017).   
1.1.2 Mechanism of RNA Interference 
Ribonucleic acid interference (RNAi) is a naturally occurring cellular mechanism for regulating gene expression that is mediated by  [CONTACT_131331] (siRNAs). Typi[INVESTIGATOR_897], 
synthetic siRNAs are 19 -base to 25 -base pair double -stranded oligonucleotides in a staggered 
duplex with a two- to four -nucleotide overhang at one or both of the 3’ ends. Such siRNAs can 
be designed to target an endogenous messenger RNA (mRNA) transcript of a given gene. When introduced into cells, the guide (or antisense) strand of the siRNA loads into an enzyme complex called the RNA -Induced Silencing Complex (RISC). This enzyme complex subsequently binds 
to its complementary mRNA sequence, mediating cleavage of the target mRNA and the suppression of the target protein e ncoded by [CONTACT_76612] ( Elbashir et  al 2001).  
Since unmodified siRNAs are rapi[INVESTIGATOR_131280] (Soutschek et  al 2004), various formulations are 
currently used to target their distribution to tissues, and to facilitate uptake of siRNAs into the relevant cell type. One approach that has been used successfully in vivo, in animal models (including in rodents and nonhuman primates) and humans employs intravenous delivery of siRNA in lipid nanoparticle (LNP) formulations 
(Soutschek et al 2004 ; Morrissey  et al 2005; Geisbert  et al 2006; Zimmermann  et al 2006; Coe
lho et  al 2020; Tabernero et  al 2013 ). Another approach for liver -specific gene silencing is 
subcutaneously administered siRNA conjugated to an N -acetylgalactosamine (GalNAc) 
carbohydrate ligand ( Ashwell  and Morell  1974). Conjugation of a triantennary GalNAc ligand 
to a siRNA enables hepatocyte binding and subsequent cellular uptake via the 
asialoglycoprotein receptor, resulting in engagement of the RNAi pathway and down regulation of hepatic proteins.  
1.1.3 Inclisiran  
Inclisiran is a chemically synthesized, subcutaneously administered, double -stranded siRNA, 
conjugated on the sense strand with triantennary GalNAc to facilitate uptake specifically by 
[CONTACT_6566]. In hepatocytes, inclisiran utilizes the RNAi mechanism and  directs catalytic 
breakdown of mRNA for PCSK9. This increases LDL -C receptor recycling and expression on 
the hepatocyte cell surface, which increases LDL -C uptake and lowers LDL -C levels in the 
circulation ( Nishikido and  Ray 2018). Inclisiran was approved by [CONTACT_90836] [ADDRESS_1179725] to diet and maximally 
tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical ASCVD who require additional lowering of LDL -C. (reference 
USPI).  
[COMPANY_001]  Confidential  Page 29 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 1.1.[ADDRESS_1179726] rands in order to target 
inclisiran to receptors on hepatocytes, thereby [CONTACT_848493] (Nishikido  and Ray  2018). In 
addition, once inclisiran is inside the cell, there is a low likelihood of off -target binding because 
inclisiran is sequestered within RISC and guided to its complementary mRNA sequence. 
Inclisiran  was well tolerated in all non -clinical studies ( Ray et al 2020 ). The most common 
findings were related to the expected pharmacological effects of inclisiran on lipid profiles and 
histopathological findings of vacuolation in hepatocytes of rats and lymph node macrophages of monkeys and the presence of basophilic granules in hepatocytes of monkeys and kidneys of rats. These microscopic findings are not considered adverse effects because they are not associated with changes in clinical pathology parameters. Liver function enzymes were only minimally to mildly increased, and were reversible following treatment- free periods, and there 
were no changes in urinalysis or urine chemistry parameters.  
1.1.5 Clinical Studies 
Inclisiran lowers LDL -C for sustained periods while only requiring twice yearly injections 
resulting in effective reductions in LDL -C (50% or more) in stable ASCVD patients in as soon 
as [ADDRESS_1179727] injection. In the double -blind, placebo-cont rolled, multicenter Phase 
III ORION trials, involving 3,655 patients (about half of which received inclisiran, n=1,833), after the initial administration of inclisiran, LDL -C levels were quickly reduced with more than 
65% of patients (placebo controlled) reaching an LDL -C <70 mg/dL when used on top of a 
maximally tolerated statin (Ray  et al 2020). Adverse events in the Phase III  trials were 
generally similar in the inclisiran and placebo groups, although injection- site adverse events 
were more frequent with inclisiran than with placebo; such reactions were generally mild, and none were severe or persistent. The phase III studies with inclisiran, however, were performed in stable ASCVD patients and did not include those who had a recent ACS event. 
1.[ADDRESS_1179728] a recent  ACS (in -patient/out -
patient) within [ADDRESS_1179729] 
an LDL -C ≥70 mg/dL despi[INVESTIGATOR_848470] -C levels and thereby [CONTACT_848494].  
The Phase III trials with inclisiran provided high -quality evidence supporting the efficacy and 
safety/tolerability of inclisiran, however, the highly controlled conditions under which these double- blind, placebo- controlled registration trials were conducted limit their ability to reflect 
the complexity and diversity of actual clinical practice. For example, adherence to lipid lowering medication that rely on patient self- administration, including statins, in clinical trials 
[COMPANY_001]  Confidential  Page 30 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 is often higher than in real -world clinical practice, in part due to the better monitoring of the 
patient. In addition, in order to meet the inclusion criteria of the inclisiran  Phase III  trials, 
participants needed to be on stable lipid -lowering therapy w ithout plans to switch therapy 
during the follow -up period, while switches in lipid lowering therapy (statin and non- statin) 
therapy are common in routine clinical practice.  
In summary, the purpose of this study is to assess the effect on LDL -C of implementation of an 
LDL -C management care pathway that includes initiation of inclisiran in participants with a 
recent hospi[INVESTIGATOR_059] (in -patient/out- patient) for an ACS with LDL -C ≥70 mg/dL despi[INVESTIGATOR_848471].  
2 Objectives, endpoints and estimands  
Table 2-1 Objectives and related endpoints 
Objective(s)  Endpoint(s)  
Primary objective(s)  Endpoint(s) for primary 
objective(s)  
• To assess the effect on LDL- C of implementation of an 
LDL-C management care pathway that includes 
initiation of inclisiran in participants with a recent hospi[INVESTIGATOR_059] (in- patient/out -patient) for an ACS with 
LDL-C ≥70 mg/dL despi[INVESTIGATOR_848472] 330  • Percent change from baseline in 
LDL-C 
• Achieving LDL- C < 70 mg/dL 
(yes, no)  
Secondary objective(s)  Endpoint(s) for secondary 
objective(s)  
• To assess (1) the absolute change from baseline in 
LDL-C level by [CONTACT_765], and (2) average of percent and 
absolute changes from baseline in LDL -C levels to 
each post -baseline visit, in the inclisiran + usual 
care group compared to usual care group at Day 330  • Absolute change from baseline in LDL-C
 
• Average percent change from 
baseline in LDL- C levels to each 
post-baseline visit  
• Average absolute change from baseline in LDL- C levels to each 
post-baseline visit  
• To assess the proportion of participants reaching pre-specified LDL -C targets in the inclisiran + usual care 
group compared to usual care group at Day 330
 • Achieving ≥ 50% reduction from baseline in LDL- C (yes, no)
 
• Achieving LDL- C < 100 mg/dL 
(yes, no) (among the subset of participants with LDL-C ≥ 100 
mg/dL at baseline)
 
• Achieving  LDL-C < 55 mg/dL 
(yes, no)  
• To assess plasma lipoproteins and triglycerides in the 
inclisiran + usual care  group compared to usual care 
group at Day 330  • Percent change and absolute change from baseline in apoB
 
• Percent change and absolute 
change from baseline in VLDL  
[COMPANY_001]  Confidential  Page 31 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
Objective(s)  Endpoint(s)  
• Percent change and absolute 
change from baseline in non-
HDL-C 
• Percent change and absolute 
change from baseline in total 
cholesterol  
• Percent change and absolute 
change from baseline in Lp(a)  
• Percent change and absolute change from baseline in HDL-C
 
• Percent change and absolute 
change from baseline in 
triglycerides  
• To assess changes in and adherence to background lipid-lowering therapy in the inclisiran + usual 
care group compared to usual care group at Day 330
 • Intensity of lipid lowering therapy (decrease in dose, no change in 
dose, increase in dose)
 
• Proportion of days covered (total number of days on either statin, 
ezetimibe, or PCSK9 inhibiting 
monoclonal antibody therapi[INVESTIGATOR_848473])
 
• Discontinuation of statin therapy 
(i.e., no statin use ≥ 30 days 
before the end- of-study visit) 
(yes, no)  
• To assess overall safety and tolerability of inclisiran  • Adverse events  
Exploratory objective(s)  Endpoint(s) for exploratory 
objective(s)  

[COMPANY_001]  Confidential  Page 32 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Objective(s)  Endpoint(s)  
• To assess major adverse cardiovascular events (MACE)  (investigator determination) in the inclisiran + 
usual care  group compared to usual care group at Day 
330
 • Cardiovascular death (yes, no)  
• Non-fatal MI (yes, no)  
• Resuscitated cardiac arrest (yes, no)
 
• Non-fatal ischemic stroke (yes, 
no) 
• Composite MACE (cardiovascular 
death, non -fatal MI, resuscitated 
cardiac arrest, or non- fatal 
ischemic stroke) (yes, no)  
2.[ADDRESS_1179730] the interpretation of the trial 
results (e.g., premature discontinuation of treatment).   
The primary clinical question of interest in this study is to evaluate the effect on LDL -C of 
implementation of an LDL -C management care pathway with inclisiran versus usual care in 
participants who are discharged after an ACS on statin therapy or have documented statin 
intolerance and do not have their LDL -C at the target level. The justification for the primary 
estimand is that it will evaluate the LDL -C lowering effect of inclisiran on both the percent 
change in LDL -C and the achievement of the target LD L-C (<70 mg/dL) compared to a usual 
care of implementation pathway in participants following a recent ACS, including potential 
changes in concomitant therapy. Further details can be found in Section  12.  
Primary estimand 1: The primary analysis of primary efficacy variable 1 (percent change from baseline in LDL -C) to address the primary objective will be based on the following estimand: 

[COMPANY_001]  Confidential  Page 33 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 • Population: Defined through appropriate inclusion/exclusion criteria to reflect the targeted population 
• Variable: Percent change from baseline in LDL -C [The primary analysis time point is 
at Day 330.] 
• Treatment: Inclisiran + usual care or usual care  
•  
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131336]. This intercurrent event will be ignored in the analysis, as the design of the trial allows for participants in the usual care group to potentially use in clisiran. 2. 
Discontinuation of study treatment.  This intercurrent event will be ignored in the analysis.  
• Summary measure: Least -squares mean difference between inclisiran + usual care 
group and usual care group 
Primary estimand 2: The primary analysis of primary efficacy variable 2 (achieving LDL -C < 
70 mg/dL) to address the primary objective will be based on the following estimand: 
• Population: Defined through appropriate inclusion/exclusion criteria to reflect the targeted population 
• Variable: Achieving LDL-C < 70 mg/dL (yes, no) [The primary analysis time point is at Day 330.] 
• Treatment: Inclisiran + usual care or usual care  
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131336]. This intercurrent event will be ignored in the analysis, as the design of the trial allows for participants in the usual care group to potentially use in clisiran. 2. 
Discontinuation of study treatment.  This intercurrent event will be ignored in the analysis.  
• Summary measure: Odds ratio of inclisiran + usual care to usual care for achieving LDL -C < 70 mg/dL 
2.2 Secondary estimands  
Not applicable. 
3 Study design  
This is a randomized, parallel -group, open- label, multicenter study comparing an LDL -C 
management strategy including inclisiran plus usual care with usual care  A total of approximately 384 participants will be randomized 1:1 to aggressive LDL -C management  with 
inclisiran plus usual care (intervention arm) and usual care (control arm). Identification of participants will take place during hospi[INVESTIGATOR_848474]. Screening of participants must take place within 5 weeks after discharge.  
Potential participants who are discharged after an ACS on statin therapy (which is considered routine care) or have documented statin intolerance will be screened and receive an LDL -C test 
[COMPANY_001]  Confidential  Page 34 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 within [ADDRESS_1179731] -discharge (to allow for the realization of the full effect of statin therapy). 
After the LDL -C test, participants with an LDL -C ≥70 mg/dL are eligible for the trial as long 
as they meet all other inclusion criteria. Participants will be  randomized to inclisiran + usual 
care or usual care. All participants will be maintained on statin therapy during inclisiran treatment, but concomitant lipid -lowering therapy and LDL -C assessments will be at the 
discretion of the treating (primary) physic ian, mimicking real- world clinical decision -making 
and enabling the evaluation of inclisiran compared to usual care in patients with a recent ACS. Usual care may therefore include addition of ezetimibe, PCSK9 -inhibiting monoclonal 
antibodies and/or commercially available inclisiran (Note: participants treated with inclisiran should not be treated with PCSK9- inhibiting monoclonal antibodies). After randomization, the 
treating physician will not have access to LDL -C values obtained as part of the study but wi ll 
be able to perform LDL -C assessments at their discretion, to mimic usual care. The rationale of 
not providing the treating physician the LDL -C values obtained as part of the study is that those 
results might influence decisions made by [CONTACT_12552]/her and could  therefore undermine “usual care”. 
Commercially available inclisiran may be used for appropriate patients in the usual care arm at the sole discretion of the treating physician, without any influence from the PI.  LDL -C 
measurement and assessment of lipid lowering medications at each visit will be performed to assess adherence to background statin therapy.  
The collection of data from trial sites through eCRFs may also be complemented with EHR data and claims data (e.g., lipid measurements and concomitant medications), if available. While study visits will be preferentially performed in -person at the study si tes, phone 
or virtual home -visits are an acceptable alternative if in -person visits are not permitted or 
impractical  (e.g., due to a public health emergency). Site or home health nursing service may 
be used to assist with blood draws and/or study medication administration if required at these visits.  Informed consent forms will be available in English and Spanish. 
Figure 3-1 Study Design 
 

[COMPANY_001]  Confidential  Page 35 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Remote procedures  
At the investigator's direction and based on benefit -risk considerations of the participant's 
clinical condition, qualifying participants may be offered the option to have certain clinical trial procedures according to Table 8 -1 Assessment schedule performed at a remote location.  
Procedures will be performed remotely under the oversight of the Investigator, who retains accountability for the oversight and all efficacy and safety decisions with delegation of tasks to an off- site healthcare professional.  
If allowable by a local Health Authority and depending on operational capabilities, phone calls, virtual contacts (e.g. tele consult) or visits by [CONTACT_131338]´s home, can replace on -site study visits for the duration of the disruption until it is safe for the 
participant to visit the site again. Any off -site healthcare professionals utilized during the trial 
must be agreed with [COMPANY_001] before use. In addition to procedures performed by [CONTACT_22885] -site 
healthcare professional,  the on- site staff will perform certain procedures remotely using tele -
visits.  
[ADDRESS_1179732] -discharge, and consideration of non- statin therapi[INVESTIGATOR_014] 
(e.g., ezetimibe and/or a PCSK9 inhibiting monoclonal antibody) if a patient has a less -than 
50% reduction in LDL -C or an LDL -C ≥70 mg/dL.  Despi[INVESTIGATOR_848475] a 
minority of patients who are eligible actually receive non -statin  therapi[INVESTIGATOR_848476] a result, most patients will not reach their target LDL -C level.  The poor 
management of blood cholesterol is partly a consequence of clinical inertia and partly a consequence of limitations of currently avail able non- statin therapi[INVESTIGATOR_014] (i.e., ezetimibe has a 
limited LDL -C lowering effect and PCSK9 inhibiting monoclonal antibodies require patient 
self-administration by [CONTACT_348434] 2 to 4 weeks). The one -year study duration of this trial 
will enable comparison  of LDL -C lowering strategies in participants following an ACS using 
inclisiran compared to usual care.  
Additional important considerations of the study design include: 
• Recruitment:  Potentially eligible participants, recently hospi[INVESTIGATOR_848461] (in -
patient/out- patient), will be identified by [CONTACT_848495]. Eligible participants will need to consent to 
having health records made available as part of the collection of medical and pharmacy claims in order to assess healthcare resource utilization during the study.  
[COMPANY_001]  Confidential  Page 36 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 • Responsibilities of principal investigator: [INVESTIGATOR_848477]'s own treating physician. As a consequence, the treating physician will not see participants more frequently due to trial participation and will not be aware of the laboratory assessments performed in the context of the study (routine or usual care laboratory tests and changes in therapy are at their discretion).   
• Open label:  The study will be performed as an open-label study to mimic decision 
making in usual care, following from the primary objective of the study. For example, if the study would have been performed as a double-blind placebo-controlled study, it would not be possible to study the effect of inclisiran treatment on statin discontinuation as participants and investigators would not be aware of treatment allocation.  
• Duration of study period:  The study is designed as a one- year trial with a total of three 
inclisiran doses. The Phase III trials of inclisiran had a follow -up duration of 18 months. 
In the Phase II trial (ORION -1), it was shown that the second dose at Day 90 lowers LDL-
C to a sligh tly greater level then after the initial administration  (Ray et al 2017). Based on 
these trials, the maximum reduction in LDL -C is achieved approximately [ADDRESS_1179733] of 
patients discontinue statin therapy in the three years following initiation of therapy (Khunti et  al 2018). A follow -up duration of one year enables: 1) observation of the 
steady -state LDL -C lowering effect of inclisiran, 2) observation of a meaningful 
difference in statin discontinuations, should such a difference exist, and 3) observation of potential diffe rences in  variables that likely require longer -term treatment of inclisiran to 
become apparent, such as patient reported outcomes.  
Implementation of a systematic LDL -C management pathway including treatment with 
inclisiran in participants who have experienced an ACS and have an LDL -C ≥70 mg/dL, despi[INVESTIGATOR_848478], could increase the proportion of participants who reach acceptable LDL -C levels and thereby [CONTACT_848496].  Inclisiran has not been previously evaluated in patients with a recent ACS. In this 
context, we aim to assess the LDL -C lowering effects of aggressive L DL-C management with 
inclisiran in patients with a previous hospi[INVESTIGATOR_848479].  
4.1.[ADDRESS_1179734] documentation of statin intolerance, at the time of identification and screening (~2 -5 wks following an ACS) without 
plans to adjust lipid lowering therapy at that point in time. Adjustments  in lipid -lowering 
therapy other than inclisiran during the study will occur at the discretion of the treating (primary) health care practitioner in both treatment groups, mimicking real -world clinical 
decision- making. Inclisiran will not be excluded from the usual care group post -approval – it is 
assumed based on historical and anticipated product uptake shortly after launch that potential inclisiran treatment in the usual care group will be minimal and thus will not significantly interfere with the study.  Participants receiving inclisiran during the trial should not be 
simultaneously treated with a PCSK9 inhibiting monoclonal antibody. 
[COMPANY_001]  Confidential  Page 37 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 4.2 Rationale for dose/regimen and duration of treatment  
Previous studies have shown that a 300 mg dose of inclisiran sodium is well tolerated and provides maximum efficacy (i.e., doses higher than 300 mg did not provide additional efficacy in LDL -C lowering). The [ADDRESS_1179735] demonstrated that the 300 mg dose of inclisiran results in sustained reductions in LDL -C (Ray et al 2017 ). A treatment duration of one year will be 
sufficient to assess changes in LDL -C due to inclisiran and changes in concomitant lipid-
lowering therapy.  
4.3 Rationale for choice of control drugs (comparator/placebo) or 
combination drugs  
Not applicable. 
4.4 Purpose and timing of interim analyses/design adaptations  
 After all participants complete their baseline visit, the demographic and baseline characteristics 
may be summarized to help design new studies.  
4.5 Risks and benefits  
Appropriate eligibility criteria and specific dose -limiting toxicity definitions, as well as specific 
dose modification and stoppi[INVESTIGATOR_004], are included in this protocol. The risk to participants in this trial may be minimized by [CONTACT_271446], as well as close clinical monito ring, and stoppi[INVESTIGATOR_004]. 
Participants taking part in this clinical study will receive statin therapy and/or other LDL -C 
lowering therapi[INVESTIGATOR_848480]. Reduction of LDL -C has been associated with reduced CV risk both by 
[CONTACT_14198][INVESTIGATOR_76582]. Modification of concomitant therapy is at the discretion of the participants’ treating physician.  Additionally, study assessments and frequent 
visits will provide close monitoring of participa nts’ conditions and may provide information 
that may benefit post- ACS patients in the future.  
Support for the planned administration of inclisiran to participants with elevated LDL -C is 
provided by [CONTACT_716]: 
• Inclisiran has been studied in a Phase III program for the patient population eligible for this study.   
• Injection site reaction is the only adverse event known to be attributed to inclisiran treatment. To date, all injection site reactions were localized, predominantly mild or 
occasionally moderate, transient, and resolved without sequelae. 
• The potential for immunogenicity of inclisiran was shown to be low. 
• Reduction of LDL-C has been associated with reduced CV risk both by [CONTACT_14198][INVESTIGATOR_131294].   
 

[COMPANY_001]  Confidential  Page 38 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Women of child -bearing potential and sexually active males must be informed that taking the 
study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study, and agree that in order to participate in the study they must adhere to the contraception requirements outlined in the exclusion criteria. If there is any question that the participant will not reliably comply, they should not be entered or continue in the study. 
4.6 Rationale for Public Health Emergency mitigation procedures  
During a Public Health emergency as declared by [CONTACT_6586], i.e. pandemic, epi[INVESTIGATOR_6519], mitigation procedures to ensure participant safety and trial integrity are listed in relevant sections. Notification of the Public h ealth emergency should be discussed 
with [COMPANY_001] prior to implementation of mitigation procedures and permitted/approved by [CONTACT_6588].  
5 Study Population  
This study will include male or female participants ≥18 years of age with a recent hospi[INVESTIGATOR_059] (in -patient/out- patient) for an ACS (within 5 weeks) and elevated LDL -C (≥70 
mg/dL) despi[INVESTIGATOR_848481]. We plan to 
randomize approximately [ADDRESS_1179736] meet all of the following criteria:  
1. Males and females ≥18 years of age  
2. Recent ACS (in -patient/out-patient) within 5 weeks of screening, defined as: 
Ischemic symptoms with unstable pattern, occurring at rest or minimal exertion within [ADDRESS_1179737] one of the following: 
a. Elevated cardiac biomarkers (cardiac troponin (cTn) or the MB fraction of creatinine kinase  (CKMB))  with at least one value above the 99th percentile of the upper 
reference limit (URL) or defined by [CONTACT_848491] -off 
values  OR 
b. Resting ECG changes consistent with ischemia or infarction AND additional evidence 
of obstructive coronary disease  
3. Serum LDL- C ≥70 mg/dL or non- HDL -C ≥100 mg/dL  
4. Fasting triglycerides <4.52 mmol/L (<400 mg/dL) at screening  
5. Calculated glomerular filtration rate >20 mL/min by [CONTACT_10495] (eGFR)  
6. Participants must be willing and able to give informed consent before initiation of any 
study related procedures and willing to comply with all required study procedures 
7. Participants are required to be on statin therapy, or have documented statin intolerance, as determined by [CONTACT_093], following hospi[INVESTIGATOR_059] (in- patient/outpatient) for an 
ACS. Statin intolerant patients are eligible if they had intolerable side effects on at least [ADDRESS_1179738] dose.  
[COMPANY_001]  Confidential  Page 39 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 5.2 Exclusion criteria 
Participants meeting any of the following criteria are not eligible for inclusion in this study.  
1. Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the participant at significant risk (according to investigator’s [or delegate] judgment) if he/she par ticipates in the 
clinical study.  
2. An underlying known disease, or surgical, physical, or medical condition that, in the 
opi[INVESTIGATOR_871] (or delegate) might interfere with interpretation of the clinical 
study results.  
3. [LOCATION_001] Heart Association (NYHA) class IIIb or IV heart failure or last known left ventricular ejection fraction <25%. 
4. Significant cardiac arrhythmia within 3 months prior to randomization that is not controlled by [CONTACT_131329].  
5. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization (assessed at screening visit) despi[INVESTIGATOR_6521]. 
6. Recurrent acute coronary syndrome event within 2 weeks prior to randomization.  
7. Coronary angiography and revascularization procedure (PCI or CABG surgery) performed within 2 weeks prior to the randomization visit or planned after randomization.   
8. Severe concomitant non- cardiovascular disease that carries the risk of reducing life 
expectancy to less than 2 years.  
9. History of malignancy that required surgery (excluding local and wide- local excision), 
radiation therapy and/or systemic therapy during the three years prior to randomization.  
10. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception during dosing of investigational drug. Basic contraception methods include: 
• Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception 
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_104] 
• Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that subject  
• Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps)  
• Use of oral (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraceptio n or placement of an intrauterine device (IUD) or intrauterine system 
(IUS)  
[COMPANY_001]  Confidential  Page 40 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 In case of use of oral contraception women should have been stable on the same pi[INVESTIGATOR_6522] a minimum of [ADDRESS_1179739] had 12 
months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age 
appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_6592]. 
11. Treatment with other investigational products or devices within 30 days or five half˗lives 
of the screening visit, whichever is longer.  
a. Approved vaccines or vaccines used under Emergency Use 
Authorization   should not be considered part of this exclusion criteria. 
Patients can receive COVID vaccines during inclisiran trials.  
b. While use of COVID anti -viral therapi[INVESTIGATOR_848482], prior to screening, they would not be considered as criteria 
for trial termination/discontinuation.  
12. History of hypersensitivity to any of the study treatments or its excipi[INVESTIGATOR_848483].  
13. Planned use of other investigational products or devices during the course of the study. 
14. Any condition that according to the investigator could interfere with the conduct of the 
study, such as but not limited to: 
a. Participants who are unable to communicate or to cooperate with the 
investigator.  
b. Unable to understand the protocol requirements, instructions and study- related 
restrictions, the nature, scope, and possible consequences of the study (including participants whose cooperation is doubtful due to drug abuse or alcohol dependency). 
c. Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study). 
d. Have any medical or surgical condition, which in the opi[INVESTIGATOR_848484]. 
e. Persons directly involved in the conduct of the study. 
15. Treatment with monoclonal antibodies directed towards PCSK9 or inclisiran within 90 days of screening. 
16. Active liver disease defined as any known current infectious, neoplastic, or metabolic 
pathology of the liver or (ii) alanine aminotransferase (ALT) elevation >3x ULN, aspartate 
aminotransferase (AST) elevation >3x ULN, or total bilirubin elevation >2x ULN  (except 
[COMPANY_001]  Confidential  Page 41 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 patients with Gilbert’s syndrome) at screening confirmed by a repeat measurement at least one week apart.  
6 Treatment 
6.1 Study treatment  
All eligible participants will be randomized to receive either inclisiran + usual care or usual care (standard of care per treating physician). The following study treatment will be provided: Inclisiran (KJX839), 284 mg, 1.5 ml Liquid in a  single- use prefi lled syringe (PFS) for s.c. 
administration.  
6.1.1 Investigational and control drugs 
Table 6-1 Investigational and control drug  
Investigational/ 
Control Drug  
(Name [CONTACT_6673])  Pharmaceutical Dosage Form  Route of Administration  Supply Type  Sponsor (global or local)  
Inclisiran, KJX839 284 mg 1.5 ml  PFS, Liquid for injection   s.c. 
Inclisiran sodium 300 mg / 1.5 ml 
(equivalent to 284 
mg of inclisiran)  Sponsor (local)  
6.1.2 Additional study treatments 
No other treatment beyond investigational drug and usual care are included in this trial. 
6.1.3 Treatment arms/group 
Participants will be assigned  at Visit 2/Baseline to one of two treatment groups (inclisiran + 
usual care and usual care) in a ratio of 1:1 to require approximately 384 participants (192 participants per treatment group) to be randomized.  
6.1.4 Treatment duration 
The planned duration of treatment is 330 days from randomization. Participants may be discontinued from treatment at any time due to adverse events, disease progression and/or at the discretion of the investigator or the participant.   
6.2 Other treatment(s)  
Not applicable 
6.2.1 Concomitant therapy 
All prior cardiovascular medications (e.g., antiplatelets (aspi[INVESTIGATOR_248], thienopyridines), non -vitamin 
K oral anticoagulants (NOACs), beta -blockers, ACE -inhibitors or ARBs, other 
antihypertensives, antidiabetics, and lipid lowering therapi[INVESTIGATOR_014]) administered before the 
[COMPANY_001]  Confidential  Page 42 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 participant is enrolled in the study but still receiving must be recorded in the appropriate Case Report Forms, or where applicable, sourced from the EHR and mapped into the clinical study.  
All medications, procedures, and significant non- drug therapi[INVESTIGATOR_014] (including physical therapy and 
blood transfusions) administered after the participant is enrolled into the study must be recorded 
on the appropriate Case Report Forms. 
Each concomitant drug must be individually assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_30791] a participant or allowing a new medication to be started. If the participant is already enrolled, contact [CONTACT_30792]. 
[IP_ADDRESS] Permitted concomitant therapy requiring caution and/or action  
Not applicable 6.2.2 Prohibited medication 
The treatments displayed in the table below are not allowed to be used simultaneously with 
inclisiran in the treatment arm.  No modifications of therapy is required or recommended in the usual care arm.  
Table 6-2 Prohibited medication 
Medication  Prohibition period  Action to be taken  
Alirocumab (Praluent)  Participants randomized to inclisiran: monoclonal antibodies directed against 
PCSK9 are prohibited for the 
full duration of the study   Discontinue PCSK9 inhibitor  
Evolocumab (Repatha)  Participants randomized to 
inclisiran: monoclonal 
antibodies directed against 
PCSK9 are prohibited for the 
full duration of the study   Discontinue PCSK9 inhibitor  
6.3 Participant numbering, treatment assignment, randomization  
6.3.1 Participant numbering 
Each participant is identified in the study by a Participant Number (Participant No.), that is assigned when the participant is enrolled for screening and is retained for the participant throughout his/her participation in the trial. A new Participant No. will be assigned at every subsequent enrollment if the participant is re -screened. The Participant No. consists of the 
Center Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential participant number suffixed to it, so th at each participant’s participation is numbered uniquely 
across the entire database. Upon signing the informed consent form, the participant is assigned to the next sequential Participant No. available to the site.  
[COMPANY_001]  Confidential  Page 43 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 6.3.[ADDRESS_1179740] will be produced by [CONTACT_90181] a validated system that automates the random assignment of medication numbers to the package containing the investigational drug(s).  
At Visit 2/Baseline, all eligible participants will be randomized via Interactive Response 
Technology (IRT) to one of the two treatment groups in 1:1 ratio (inclisiran + usual care vs usual care). The investigator or his/her delegate will contact [CONTACT_6608]/exclusion criteria. The IRT will assign a randomization number to the participant, which will be used to link the participant to a treatment group and will specify a unique medication number f or the first package of study treatment to be dispensed 
to the participant. 
The randomization scheme for participants will be reviewed and approved by a member of the 
[COMPANY_001] Biometrics group.  
6.4 Treatment blinding  
This is an open- label study and study treatment is not blinded, thus treatments will be known to 
participants, investigator staff, including persons performing the study assessments.  
6.5 Dose escalation and dose modification  
Dose interruptions for the investigational study medication (inclisiran) are not permitted.  
If a planned dose is missed by [CONTACT_21316] 3 months, administer inclisiran and maintain dosing according to the participant’s original schedule. If a planned dose is missed by [CONTACT_726] [ADDRESS_1179741] be recorded on the inclisiran Dose Administration case report form for 
the investigational study drug. 
6.5.1 Dose modifications  
Study drug administration of inclisiran [inclisiran (KJX839), 284 mg liquid in PFS, 1.5 ml] 
should be temporarily interrupted or permanently discontinued in participants with:  
1. Intolerable AEs, or if the investigator believes that continuing dosing will be detrimental to the participant’s mental or physical health.  This includes severe or serious reactions 
at the injection site and any anaphylactic type reactions. 
2. Liver laboratory values meeting the study drug interruption criteria listed in Table 16 -4 
and Table 16-5.   
[COMPANY_001]  Confidential  Page 44 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 3. Unexplained creatine kinase (CK) values >[ADDRESS_1179742] when the CK elevation is associated with muscle pain, muscle tenderness and/or muscle weakness, or new onset renal dysfunction. 
Study treatment may be restarted at the discretion of the investigator, if the reason for discontinuation has resolved. 
The dose interruptions must be recorded on an appropriate eCRF. 
6.5.2 Follow -up for toxicities 
[IP_ADDRESS] Follow up on potential drug- induced liver injury (DILI) cases 
 Participants with transaminase increase combined with total bilirubin increase may be 
indicative of potentially severe DILI, and should be considered as clinically important events and assessed appropriately to establish the diagnosis. The required clinica l information, as 
detailed below, should be sought to obtain the medical diagnosis of the most likely cause of the observed laboratory abnormalities.  
The threshold for potential DILI may depend on the participant’s baseline AST/ALT and total bilirubin value; participants meeting any of the following criteria will require further follow -up 
as outlined below: 
• For participants with normal ALT and AST and total bilirubin value at baseline: AST or ALT > 3.[ADDRESS_1179743] combined with total bilirubin > 2.[ADDRESS_1179744] 
• For participants with elevated AST or ALT or total bilirubin value at baseline: [AST or ALT > 2 x baseline] OR [AST or ALT >300 U/L] whichever occurs first combined with [total bilirubin > 2 x baseline AND > 2.[ADDRESS_1179745] bilirubin, gamma - 
glutamyl transferase (GGT), glutamate dehydrogenase (GLDH), prothrombin time 
(PT)/International Normalized Ratio (INR), alkaline phosphatase (ALP), albumin, an d CK.  
Perform relevant examinations (Ultrasound or Magnetic resonance imaging (MRI), Endoscopic retrograde cholangiopancreatography (ERCP)) as appropriate, to rule out an extrahepatic cause of cholestasis. Cholestasis (is defined as an ALP elevation > 2.[ADDRESS_1179746] with R value < 2 in participants without bone metastasis, or elevation of the liver- specific ALP isoenzyme in 
participants with bone metastasis). Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN for both values. It  denotes whether the relative pattern of ALT 
and/or ALP elevation is due to cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) liver injury. For children, there are caveats to calculating the R -ratio as normal levels of 
ALP are higher than in adults with standard ranges varying by [CONTACT_302003]. In clinical situations where it is suspected that ALP elevations are from an extrahepatic source, the GGT 
[COMPANY_001]  Confidential  Page 45 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 can be used if available. GGT may be less specific than ALP as a marker of cholestatic injury, since GGT can also be elevated by [CONTACT_6613]. It is more sensitive than ALP for detecting bile duct injury (https://livertox.nih.gov/rucam.html). 
Table [ADDRESS_1179747] (LFT) 
abnormalities.  
Table 6-3  Guidance on specific clinical and diagnostic assessments which can 
be performed to rule out possible alternative causes of observed LFT 
abnormalities 
Disease  Assessment  
Hepatitis A, B, C, E  IgM anti -HAV; HBsAg, IgM & IgG anti- HBc, HBV 
DNA; anti -HCV, HCV RNA, IgM & IgG anti -HEV, 
HEV RNA  
CMV, HSV, EBV infection  IgM & IgG anti -CMV, IgM & IgG anti -HSV; IgM & 
IgG anti -EBV 
Autoimmune hepatitis  ANA & ASMA titers, total IgM, IgG, IgE, IgA  
Alcoholic hepatitis  Ethanol history, GGT, MCV, CD -transferrin  
Nonalcoholic steatohepatitis  Ultrasound or MRI  
Hypoxic/ischemic hepatopathy  Medical history: acute or chronic CHF, 
hypotension, hypoxia, hepatic venous occlusion. 
Ultrasound or MRI  
Biliary tract disease  Ultrasound or MRI, ERCP as appropriate  
Wilson disease (if <40 yrs old)  Caeruloplasmin  
Hemochromatosis  Ferritin, transferrin  
Alpha -1-antitrypsin deficiency  Alpha -1-antitrypsin  
Other causes should also be considered based upon participants’ medical history 
(hyperthyroidism / thyrotoxic hepatitis – T3, T4, TSH; CVD / ischemic hepatitis – ECG, prior 
hypotensive epi[INVESTIGATOR_1841]; T1D / glycogenic hepatitis). 
Following appropriate causality assessments, as outlined above, the causality of the treatment 
is estimated as “probable” i.e. >50% likely, if it appears greater than all other possible causes of liver injury combined. The term “treatment -induced” indicate s probably caused by [CONTACT_6614], not by [CONTACT_6615], and only such a case can be considered a DILI case and should be reported as an SAE.  
All cases confirmed on repeat testing meeting the laboratory criteria defined above, with no 
other alternative cause for LFT abnormalities identified, should be considered as “medically 
significant,” and thus, meet the definition of SAE and should be repor ted as SAE using the term 
“potential treatment -induced liver injury.” All events should be followed up with the outcome 
clearly documented. 
[COMPANY_001]  Confidential  Page 46 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 6.6 Additional treatment guidance  
6.6.1 Treatment compliance 
Compliance will be ensured by [CONTACT_1755]/or study personnel at each dosing visit. This information should be captured in the source document at each visit. Study drug (inclisiran) accountability will also be determined by [CONTACT_848497]. 
Duration of study drug exposure will be calculated based upon the dates recorded in the eCRF.  
6.7 Preparation and dispensation  
Each study site will be supplied with study drug in packaging as described under investigational 
and control drugs section ( Section 6.1.1).  
A unique medication number is printed on the study medication label. 
Investigator staff will identify the study medication kits to dispense to the participant by 
[CONTACT_105245](s). The study medication has a 2- part 
label (base plus tear -off label), immediately before dispensing the medication kit to the 
participant, site personnel will detach the outer part of the label from the packaging and affix it to the source document. 
All kits of study treatment assigned by [CONTACT_6607].  
As per Section  4.6, during a Public Health emergency that limits or prevents on- site study visits, 
a home health nurse is permitted to administer the study medication at a participant's home (if 
allowed by [CONTACT_848498]) in the 
event the Investigator has decided that an on -site visit by [CONTACT_848499]. The dispatch of study medication from the site to the participant’s home remains under the accountability of the Investigator. 
6.7.1 Handling of study treatment and additional treatment  
[IP_ADDRESS] Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored 
safely and properly and kept in a secured location to which only the investigator and designated site personnel have access. Upon receipt, all study treatment must be stored according to the instructions specified on the labels.  
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints 
are to be reported to the respective [COMPANY_001]  US Quality Assurance representative.  
Medication labels will include storage conditions for the study treatment but no information about the participant except for the medication number . 
The investigator must maintain an accurate record of the shipment and dispensing of study treatment in a drug accountability log. Monitoring of drug accountability will be performed by [CONTACT_30798].  
[COMPANY_001]  Confidential  Page 47 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 At the conclusion of the study, and as appropriate during the course of the study, the investigator will return all unused study treatment, packaging, drug labels, and a copy of the completed drug accountability log to the [COMPANY_001]  monitor or to the Novart is address provided in the 
investigator folder at each site.  
6.7.[ADDRESS_1179748] [Inclisiran (KJX839), 284 mg Liquid PFS, 1.5 ml] will be provided by [CONTACT_456]. Medication labels will comply with regulatory requirements. The storage conditions will be described on the medication label. 
The container closure system for the prefilled syringe consists of a Type I glass syringe with a 
stainless steel 27G 1/2" staked needle covered by a removable rigid needle shield and Flurotech covered bromobutyl plunger. 
Table 6-4 Dose and treatment schedule 
Investigational / Control Drug  
(Name [CONTACT_131377])  Dose  Frequency and/or Regimen  
Inclisiran (KJX839), 284 mg 
Liquid in PFS, 1.5 mL  Inclisiran sodium 300 mg/1.5 
mL (equivalent to 284 mg 
inclisiran), s.c.  use Initially, 90 days later, 180 days 
after the second dose  
Participants will be administered a single SC injection of 300 mg Inclisiran sodium for injection 
at predefined time points as described in the Schedule of Assessments ( Table 8 -1). 
Investigational product injection will be administered by [CONTACT_302006]. The site of injection is the abdomen, arm or thigh. Do not inject into areas of active skin disease or injury such as sunburns, skin rashes, inflammation, tattoos or skin infections.   
All kits of study treatment assigned by [CONTACT_6607].  
7 Informed consent procedures  
Eligible participants may only be included in the study after providing (witnessed, where required by [CONTACT_6617]), IRB/IEC-approved informed consent. 
If applicable, in cases where the participant's representative(s) gives consent (if allowed 
according to local requirements), the participant must be informed about the study to the extent 
possible given his/her understanding. If the participant  is capable of doing so, he/she must 
indicate agreement by [CONTACT_30803]. 
Informed consent must be obtained before conducting any study- specific procedures (e.g., all 
of the procedures described in the protocol). The process of obtaining informed consent must 
be documented in the participant source documents.  
[COMPANY_001]  will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory requirements and is considered 
[COMPANY_001]  Confidential  Page 49 of 94 
Amended Clinical Trial Protocol ( v04 Clean)   Protocol No. CKJX839A1US01  
 
 
 Participants will have to comply with the following restrictions during the study:  
• Participants need to fast for at least 8 hours for all visits (measurement of lipi[INVESTIGATOR_805]/lipoproteins and blood glucose requires participants to be fasting).  If the participant has not fasted, the collection of laboratory evaluations must be rescheduled.  
• Blood donation will not be allowed at any time during the study 
The “X” in the table denotes the assessments to be recorded in the clinical database or received electronically from a vendor. The “S” in the table denotes the assessments that are only in the participant’s source documentation and do not need to be recorded in the clinical database.  
As per Section  4.6, during a Public Health emergency that limits or prevents on- site study visits, 
alternative methods of providing continuing care may be implemented by [CONTACT_6623]. If allowable by a local Health Authority and depending on op erational 
capabilities, phone calls, virtual contacts (e.g. tele consult) or visits by [CONTACT_6624]/ home nursing staff to the participant´s home, can replace on -site study visits, for the duration of the disruption 
until it is safe for the participant to vi sit the site again.  
If a public health emergency limits or prevents on- site study visits, alternative methods of 
providing continuing care may be implemented. Virtual visits [e.g., phone calls, video visits (preferred)] or visits by [CONTACT_6624]/home nursing service to the part icipant´s home depending on 
local regulations and capabilities, can replace on -site study visits, for the duration of a public 
health emergency until it is safe for the participant to visit the site again.  
Unscheduled Visits  
Participants may be seen at any time for an unscheduled visit, e.g., if they experience deterioration or AEs that in the opi[INVESTIGATOR_689]/qualified site staff requires closer monitoring. The assessment(s) performed at an unscheduled visit must i nclude at a minimum: 
an assessment of concomitant medications, vital signs, and an AE/SAE assessment. Any additional assessments performed are at the Investigator/qualified site staff’s discretion.  
[COMPANY_001]  Confidential  Page 52 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 8.1 Screening  
A participant’s eligibility for the study will be assessed during the 30 day screening period (Day -30 to Day - 1). Screening is flexible in duration based on the time required for participants to 
be evaluated for eligibility.  It is permissible to re -screen  a participant if s/he fails the initial 
screening; however, each case must be discussed and agreed with the Sponsor on a case-by-case basis.  
8.1.1 Information to be collected on screening failures  
Participants who sign an informed consent form and subsequently found to be ineligible will be considered a screen failure.  It is permissible to re -screen a participant if  he/she fails the initial 
screening; however, each case must be discussed and agreed with the Sponsor on a case -by-
case basis. If the re -screen is approved, a new participant number will be allocated to the 
participant and he/she will need to re -perform all Visit [ADDRESS_1179749] pro vide new written informed consent before they are re -
screened.  
The reason for screen failure should be entered on the applicable Case Report Form. The demographic information, informed consent, and Inclusion/Exclusion pages must also be completed for screen failure participants. No other data will be entered into the clinical database for participants who are screen failures, unless the participant experienced a serious adverse event during the screening phase (see SAE section for reporting details). If the participant fails to be randomized, the IRT must be notified w ithin 2 days of the screen failure that the participant 
was not randomized. 
Participants who are randomized and fail to start treatment (e.g., participants randomized in 
error) will be considered an early terminator. The reason for early termination should be recorded on the appropriate Case Report Form. 
8.2 Participant demographics/other baseline characteristics  
Participant demographic and baseline characteristic data to be collected on all participants include age, sex, race, ethnicity, and source of patient referral. Any relevant medical history including surgical/medical procedures, protocol solicited medical h istory, and/or current 
medical conditions before obtaining informed consent will be recorded in the Medical History eCRF.  A detailed medical history (including cardiovascular and other conditions relevant to the study population to be enrolled) and current medical conditions present, including the presentation and management of index MI event will also be recorded.  Where possible, diagnoses and not symptoms, will be recorded. All medications and relevant medical histories will be recorded on the corresponding eCRFs.  
8.3 Efficacy  
The primary efficacy variables are the following:  
1. Percent change from baseline in LDL -C 
2. Achieving LDL-C < 70 mg/dL (yes, no) 
[COMPANY_001]  Confidential  Page 55 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 8.[ADDRESS_1179750] of monitoring and recording of all adverse events and serious adverse events, evaluation of hematology, blood chemistry and urine values, regular measurement of vital signs and the performance of physical examinations.  
As per Section 4.6, during a Public Health emergency that limits or prevents on- site study visits 
regular phone or virtual calls should occur for safety monitoring and discussion of the participant´s health status until the participant can again visit the site. If a participant cannot visit the site to have pregnancy tests done, a home urine pregnancy test kit may be used. Participants can perform the urine pregnancy test at home at the time of the scheduled visit and report the result to the site, or a communication process  should be established with the 
participant so that the site is informed of the pregnancy test results. If a visit by [CONTACT_131354], it is important that participants are instructed to perform the urine pregnancy test first and only if the test result is negative proceed with the administration of the study treatment.  
Safety assessments are specified below with the assessment schedule detailing when each assessment is to be performed.  
For details on AE collection and reporting, refer to AE section. Please consult the Investigator's Brochure for the specific (non-routine) safety assessments.  
Table 8-2 Safety Assessment  
Assessment  Specification  
Physical   A complete physical examination will include the 
examination of general appearance, skin, neck 
(including thyroid), eyes, ears, nose, throat, 
lungs, heart, abdomen, back, lymph nodes, 
extremities, vascular, and neurological. If indicated based on medical history and/or 
symptoms, rectal, external genitalia, breast, and pelvic exams will be performed.  
A short physical exam will include the examination of general appearance and vital 
signs (blood pressure [SBP and DBP] and pulse). A short physical exam will be at all visits 
starting from visit 3 except where a complete physical examination is required (see above).  
Information for all physical examinations must be included in the source documentation at the 
study site. Clinically relevant findings that are present prior to signing informed consent must 
be recorded on the appropriate CRF that 
captures medical history.  Significant findings 
made after signing informed consent which meet 
the definition of an Adverse Event must be 
recorded as an adverse event.  
[COMPANY_001]  Confidential  Page 56 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 Vital signs  Vital signs include BP and pulse measurements. 
After the participant has been sitting for five minutes, with back supported and both feet placed on the floor, systolic and diastolic blood 
pressure will be measured three times using a 
validated device, e.g.  standard 
sphygmomanometer or an automated BP 
device, with an appropriately sized cuff. The 
repeat sitting measurements will be made at 1 - 
2 minute intervals and the mean of the three measurements will be used. In case the cuff sizes available are not large enough for the 
participant's arm circumference, a 
sphygmomanometer with an appropriately sized 
cuff may be used.  
Height and weight  Height in centimeters (cm) and body weight (to the nearest 0.1 kilogram (kg) in indoor clothing, 
but without shoes) will be measured.  
8.4.1 Laboratory evaluations  
Specimens will be obtained at the time points in the Assessment Schedule ( Table 8 -1). 
A central laboratory will be used for analysis of all specimens collected, with the exception of urine pregnancy tests and urine dipstick tests, which will be done locally at the site (using testing materials supplied by [CONTACT_2237]). Serum preg nancy tests at screening will be done 
by [CONTACT_2237]. Details on the collections, shipment of samples and reporting of results by [CONTACT_131356] a Laboratory Manual.  
In case of abnormal dipstick urinalysis results, microscopy and other assessments (e.g. serum 
albumin and serum total protein) will be performed at the local laboratory and the abnormality 
recorded as an AE.  
Clinically significant abnormalities must be recorded as either medical history/current medical conditions or adverse events as appropriate.  
Clinically notable laboratory findings are defined in Section  16.[ADDRESS_1179751] be entered on the patient's AE eCRF. If the laboratory abnormality is the primary reason for an unforeseen hospi[INVESTIGATOR_131304], then the procedure for rapid notification of SAEs must be followed. Likewise, if the laboratory abnormality leads to discontinuation from the study drug (temporarily or permanently), the patient must be followed until the abnormality resolves or until it is judged to be permanent. This investigation may include continued monitoring by [CONTACT_848500] t esting or by [CONTACT_848501].  
[COMPANY_001]  Confidential  Page 57 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 As per  Section  4.6, during a Public Health emergency that limits or prevents on -site study visits, 
if a visit by [CONTACT_6624]/home nursing staff is arranged, specimen samples should be collected during the visit and processed and handled in line with the study laboratory manual.  
Table 8-[ADDRESS_1179752] Name  
[CONTACT_6675], Hemoglobin, MCH, MCHC, MCV, 
Platelet count,  White blood cell count with 
Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Bands, 
Other)  
Chemistry  Full serum chemistry:   Albumin, Alkaline 
phosphatase (ALP), ALT, AST, Gamma -
glutamyl -transferase (GGT), Lactate 
dehydrogenase (LDH), Bicarbonate, Calcium, 
Magnesium, inorganic Phosphate, Chloride, 
Sodium, Potassium, Creatinine, estimated 
Glomerular Filtration Rate (eGFR), Creatine 
kinase (CK), Direct Bilirubin, Indirect Bilirubin, Total Bilirubin (TBL), Total Cholesterol, LDL -C 
(direct), VLDL, HDL -C. Apolipoprotein B, Total 
Protein, Triglycerides, Blood Urea Nitrogen (BUN) or Urea, Uric Acid, Amylase, Lipas e, 
Hemoglobin A1C, Glucose (fasting) and 
glycated hemoglobin (HbA1C)  
Limited serum chemistry  (ONLY):  AST, ALT, 
ALP, GGT, TBL, CK, creatinine, eGFR, fasting 
glucose and HbA1C  
Coagulation  Prothrombin Time (PT), International Normalized 
Ratio (INR) and Activated Partial 
Thromboplastin Time (aPTT)  
Urinalysis  Macroscopic Panel (Dipstick) (Color, Bilirubin, 
Red Blood Cells/Erythrocytes, Glucose, 
Ketones, White Blood Cells/Leukocytes, Nitrite, pH, Protein, Specific Gravity, Urobilinogen)  
Microscopic Panel (only performed in the event of abnormalities) (Red Blood Cells, White Blood 
Cells, Casts, Crystals, Bacteria, Epi[INVESTIGATOR_1663])  
Hepatitis markers  HBV- DNA, HBsAg, HBsAb, HBcAb, HCV RNA-
PCR (polymerase chain reaction) (screening 
visit) 
Additional tests  Lipoprotein(a) (Lp(a))  
Pregnancy Test  Serum / Urine pregnancy test  
8.4.2 Electrocardiogram (ECG)  
A standard [ADDRESS_1179753] be made 
by a qualified physician and documented on the ECG section of the eCRF. Each ECG tracing should be labeled with the study, participant number and date and kept in the source documents at the study site.  

[COMPANY_001]  Confidential  Page 58 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 Clinically significant abnormalities must be recorded on the CRF as either medical history/current medical conditions or adverse events as appropriate.  
8.4.[ADDRESS_1179754] 
(hCG) performed at Visit 1 (central lab). In addition, these participants will have a urine pregnancy test conducted at the local site for Visits 2, 3, [ADDRESS_1179755] at home and report the result to the site. If a visit by [CONTACT_6624]/home nursing staff is arranged, it is important that participants perform the urine pregnancy test first, and only if the test result is negative, proceed with the administration of the study treatment. 
8.4.4 Other safety evaluations  
Injection site reactions  
Injection site reactions (ISR) should be monitored at each visit from the Randomization (Day 
1) visit onwards ( Table 8 -1) and through additional contacts with the participant between visits 
as needed.  ISR including individual signs or symptoms at the injection site following study treatment administration should be recorded on an appropriate eCRF page.  Every effort should be made to follow-up with the participant until resolution of the ISR. 
Anaphylactic reactions  
Potential anaphylactic reactions should be assessed by [CONTACT_131358]  16.4  
(Appendix 4).  Hyperglycemia -related events  
Laboratory results and newly added concomitant medications should be checked for potential 
hyperglycemia- related AEs.   
‘New onset of diabetes’ should be reported as AE on the eCRF in participants with no medical history of diabetes when: 
• HbA1c becomes ≥6.5% and/or  
• Two consecutive values of FPG are ≥126 mg/dL (7.0 mmol/L)  
• If a new concomitant medication for control of plasma glucose is added, further information to assess for a diagnosis of new onset diabetes will need to be collected  
‘Worsening of glycemic control’ should be reported as AE on the eCRF in participants with a medical history of diabetes (HbA1c ≥6.5% at baseline) when:  
• HbA1c increases from baseline >0.5%  
[COMPANY_001]  Confidential  Page 61 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 If discontinuation of study treatment occurs, the investigator should make a reasonable effort to understand the primary reason for the participant’s premature discontinuation of study treatment and record this information.  
Participants who discontinue study treatment or who decide they do not wish to participate in the study further should NOT be considered withdrawn from the study UNLESS they withdraw their consent (see 'Withdrawal of Informed Consent' section). Where possible, they should return for the assessments indicated in the Assessment Schedule. If they fail to return for these assessments for unknown reasons, every effort (e.g., telephone, e -mail, letter) should be 
made to contact [CONTACT_2299]/pre -designated cont act as specified in the lost to follow -up 
section. This contact [CONTACT_6636].  Unless a 
participant withdraws informed consent, personal and coded data are able to be collected in accordance with the infor med consent form. 
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact [CONTACT_6635], or with a person pre -designated by [CONTACT_2416]. This telephone contact [CONTACT_6636].  
After study treatment discontinuation, at a minimum, in abbreviated visits, the following data should be collected at clinic visits or via telephone/email contact:  
• New / concomitant treatments  
• Adverse Events / Serious Adverse Events  
The investigator must also contact [CONTACT_6637]’s discontinuation from study treatment. 
9.1.2 Withdrawal of informed consent  
Participants may voluntarily withdraw consent to participate in the study for any reason at any 
time. Withdrawal of consent occurs only when a participant: 
• Does not want to participate in the study anymore, 
and 
• Does not want any further visits or assessments  
and • Does not want any further study related contacts 
In this situation, the investigator should make a reasonable effort (e.g., telephone, e -mail, letter) 
to understand the primary reason for the participant’s decision to withdraw his/her consent and 
record this information.  
Study treatment for participants in the inclisiran + usual care treatment group must be discontinued with no more inclisiran injections planned. In both the inclisiran + usual care and the usual care group no further assessments are to be conducted, and the data that would have been collected at subsequent visits will be considered missing.  
Further attempts to contact [CONTACT_6639] -up. 
[COMPANY_001]  Confidential  Page 62 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 All efforts should be made to complete the assessments prior to study discontinuation. A final evaluation at the time of the participant’s study discontinuation should be made as detailed in the assessment table.  
[COMPANY_001]  will continue to retain and use all research results (data) that have already been 
collected for the study evaluation.  
9.1.[ADDRESS_1179756] show "due diligence" by [CONTACT_6638], e.g., dates of telephone calls, registered letters, etc. A participant should not be considered as lost to follow -
up until due diligence has been completed or until the end of the study. 
9.1.4 Early study termination by [CONTACT_30815].  
Reasons for early termination, include the following: 
• Unexpected, significant, or unacceptable safety risk to participants enrolled in the 
study 
• Decision based on recommendations from applicable board(s) after review of safety and efficacy data  
• Discontinuation of study drug development 
In taking the decision to terminate, [COMPANY_001]  will always consider participant welfare and safety. 
Should early termination be necessary, participants must be seen as soon as possible and treated 
as a prematurely withdrawn participant. The investigator may  be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the protection of the participant’s interests. The investigator or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the early termination of the trial.   
9.[ADDRESS_1179757] -study treatment  
At the study completion/end of study visit, including participants who are prematurely withdrawn from the study, the referring or primary physician will continue to provide ongoing medical care. When the participant has completed all scheduled study assessments, the investigator must call the IRT to record the participant completion in the IRT.  
Study completion is defined as when the last participant finishes their Study Completion visit and any repeat assessments associated with this visit have been documented and followed -up 
appropriately by [CONTACT_1720], in the event of an early study termination decision, the date of that decision (e.g., each participant will be required to complete the study in its entirety and 
thereafter there will be no further study treatments provided (i.e., no further inclisiran injections 
will be conducted). 
For study participants who have successfully completed the study, further guidance will be 
provided separately concerning continuation of treatment and access to investigational drug.  This guidance will be provided to sites prior to the completion visit of the first patient 
[COMPANY_001]  Confidential  Page 63 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 (first patient last visit). For study participants who terminate prior to the end of the study or who withdraw from treatment, continuing treatment should be managed by [CONTACT_1755]/or referring or primary physician  
10 Safety monitoring and reporting  
10.1 Definition of adverse events and reporting requirements  
10.1.1 Adverse events 
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant after providing written informed consent for participa tion in the study. 
Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
The investigator has the responsibility for managing the safety of individual participant and identifying adverse events. 
[COMPANY_001]  qualified medical personnel will be readily available to advise on trial related medical 
questions or problems.  
The occurrence of adverse events must be sought by [CONTACT_105]- directive questioning of the participant 
at each visit during the study. Adverse events also may be detected when they are volunteered 
by [CONTACT_6643], laboratory test findings, or other assessments.   
Adverse events must be recorded under the signs, symptoms, or diagnosis associated with them, accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to Section  10.1.2):  
1. The severity grade  
• mild: usually transient in nature and generally not interfering with normal activities  
• moderate: sufficiently discomforting to interfere with normal activities  
• severe: prevents normal activities  
2. Its relationship to the study treatment. If the event is due to lack of efficacy or progression 
of underlying illness (i.e., progression of the study indication) the assessment of causality 
will usually be ‘Not suspected.’ The rationale for this guidance is that the symptoms of a lack of efficacy or progression of underlying illness are not caused by [CONTACT_6645], they happen in spi[INVESTIGATOR_6532]/or both lack of efficacy and progression of underlying disease can only be evaluated meaningfully by [CONTACT_6646], not on a single participant  
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not recovered/not resolved must be reported  
4. Whether it constitutes a SAE (see Section  10.1.2 for definition of SAE) and which 
seriousness criteria have been met  
5. Action taken regarding study treatment. 
[COMPANY_001]  Confidential  Page 64 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 All adverse events must be treated appropriately. Treatment may include one or more of the following:  
• Dose not changed 
• Dose Reduced/increased  
• Drug interrupted/withdrawn  
6. Its outcome  (i.e., recovery status or whether it was fatal)  
Conditions that were already present at the time of informed consent should be recorded in medical history of the participant.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Adverse event monitoring should be continued for at least [ADDRESS_1179758] be followed until its resolution or until it is judged to 
be permanent (e.g., continuing at the end of the study), and assessment must be made at each visit (or more frequently, if necessary) of any changes in severity, the suspected relationship to the interventions required to treat it, and the outcome.  
Information about adverse drug reactions for the investigational drug can be found in the Investigator's Brochure (IB).  
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:  
• they induce clinical signs or symptoms  
• they are considered clinically significant  
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a review of values outside of reference ranges/clinically notable ranges, significant changes from baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_258382]. Alert ranges for laboratory abnormalities are included in Section  16.1  (Appendix 1). 
10.1.2 Serious adverse events 
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s), symptom(s), or medical conditions(s) which meets any one of the following criteria:  
• fatal 
• life-threatening  
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have caused death if it were more severe (please refer to the ICH-E2D Guidelines). 
• results in persistent or significant disability/incapacity  
[COMPANY_001]  Confidential  Page 65 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 • constitutes a congenital anomaly/birth defect 
• requires inpatient hospi[INVESTIGATOR_1081], unless hospi[INVESTIGATOR_062]:  
- routine treatment or monitoring of the studied indication, not associated with any deterioration in condition 
- elective or pre -planned treatment for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
- social reasons and respi[INVESTIGATOR_6534]’s general condition 
- treatment on an emergency outpatient basis for an event not fulfilling any of the definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
• is medically significant, e.g., defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above 
Medical and scientific judgment should be exercised in deciding whether other situations should be considered serious reactions, such as important medical events that might not be immediately life threatening or result in death or hospi[INVESTIGATOR_157051]. Such events should be considered as “medically significant.” Examples of such events are intensive treatment in an emergency room or at home for al lergic bronchospasm, blood dyscrasias, or convulsions that 
do not result in hospi[INVESTIGATOR_6536]  (please refer to the ICH-
E2D Guidelines ). 
All new malignant neoplasms will be assessed as serious under “medically significant” if other seriousness criteria are not met  and the malignant neoplasm is not a disease progression of the 
study indication.  
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.  
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.  
10.1.[ADDRESS_1179759] be reported as follow -up to the original epi[INVESTIGATOR_30755] 24 hours of the investigator receiving the follow -up informatio n. An SAE occurring at a 
[COMPANY_001]  Confidential  Page 66 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 different time interval or otherwise considered completely unrelated to a previously reported one must be reported separately as a new event.  
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new occurrence) and is thought to be related to the study treatment, a CMO & PS Department associate may urgently require further information from the investigator fo r health authority 
reporting. [COMPANY_001]  may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study with the same study treatment that this SAE has been reported. 
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 2011/C 172/[ADDRESS_1179760] be reported to [COMPANY_001]  within 24 hours of learning of its 
occurrence. The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded and reported by [CONTACT_332028] (CMO&PS). Pregnancy follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study treatment and 
any pregnancy outcome. Any SAE experienced during pregnancy must be reported. 
10.1.5 Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, participant or consumer (EMA definition). 
Misuse refers to situations where the medicinal product is intentionally and inappropriately used 
not in accordance with the protocol. 
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by [CONTACT_3584]. 
Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to Safety only if associated with an SAE. Misuse or abuse will be coll ected and reported in the 
safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator’s awareness.  
[COMPANY_001]  Confidential  Page 67 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse 
Treatment error type  Document in Dosing 
CRF (Yes/No)  Document in AE 
eCRF  Complete SAE form  
Unintentional study 
treatment error  Yes Only if associated with 
an AE  Only if associated with 
an SAE  
Misuse/Abuse  Yes Yes Yes, even if not 
associated with a SAE  
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections.  
10.2 Additional Safety Monitoring  
10.2.1 Liver safety monitoring 
To ensure participant safety and enhance reliability in determining the hepatotoxic potential of an investigational drug, a standardized process for identification, monitoring and evaluation of liver events has to be followed. 
Please refer to Appendix 2 (Section 16- 2) for complete definitions of liver laboratory triggers.  
Once a participant is exposed to study treatment, every liver event defined in Table 16-3 should 
be followed up by [CONTACT_6648], as summarized below. Additional details on actions required in case of liver events are outlined in Table 16-4  
and Table 16 -5. Repeat liver chemistry tests (i.e., ALT, AST, TBL, PT/INR, ALP and GGT) to 
confirm elevation.  
• These liver chemistry repeats will be performed using the central laboratory. If results will not be available from the central laboratory, then the repeats can also be performed at a local laboratory to monitor the safety of the participant. If a liver event is subsequently reported, any local liver chemistry tests previously conducted that are associated with this event should have results recorded on the appropriate CRF. 
• If the initial elevation is confirmed, close observation of the participant will be initiated, including consideration of treatment interruption if deemed appropriate. 
• Discontinuation of the investigational drug (refer to the Discontinuation of study treatment section), if appropriate  
• Hospi[INVESTIGATOR_6539]  
• Causality assessment of the liver event  
• Thorough follow-up of the liver event can include based on investigator's discretion:  
- serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease 
All follow -up information and procedures performed must be recorded as appropriate in the 
eCRF.  
[COMPANY_001]  Confidential  Page 68 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 10.2.2 Renal safety monitoring 
To ensure participant safety and enhance reliability in determining the nephrotoxicity potential of an investigational drug, a standardized process for identification, monitoring and evaluation of renal events has to be followed. Every renal laboratory tri gger or renal event as defined 
in Table 16-6 in Appendix 3 ( Section 16.3) should be followed up by [CONTACT_848502] 16-7 in Appendix 3 ( Section 16.3).  
10.2.3 Steering Committee  
A Steering Committee (SC) for this study will be established comprising medical experts and/or clinical investigators participating in the trial and [COMPANY_001] representatives from the Clinical Trial Team. The SC will ensure transparent management of the stu dy according to the protocol 
through recommending and approving modifications as circumstances require. The SC will provide input to the clinical study protocol and potential amendments to the clinical study protocol. Together with the clinical trial team,  the SC will also develop recommendations for 
publications of study results including authorship rules. 
[ADDRESS_1179761] any complications and potential drawbacks of the collection. 
11.1 Data collection  
Electronic CRF Collection  
Designated investigator staff will enter some or all of the data required by [CONTACT_5374] (eCRF). The eCRFs have been built using fully validated secure web-enabled software that conforms to [ADDRESS_1179762] been trained in the use of the EDC system and data entry guidelines. Automatic validation program checks for data discrepancies in the eCRFs will be applied allowing modification and/or verification of the entered data by [CONTACT_6649].  
The investigator/designee is responsible for assuring that the data (recorded on CRFs), (entered into CRF) is complete, accurate, and that entry and updates are performed in a timely manner. The investigator must certify that the data entered are complete and accurate.   
After final database lock, the investigator will receive copi[INVESTIGATOR_848485].  
All data should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification.  
[COMPANY_001]  Confidential  Page 69 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 11.2 Database management and quality control  
[COMPANY_001]  personnel (or designated CRO) will review the data entered by [CONTACT_49432]. Electronic data queries stating the nature of the problem and requesting clarification will be created for discrepancies and missing  values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data. 
Concomitant treatments and prior medications entered into the database will be coded using the 
World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical classification system. Medical history/current medical con ditions and 
adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology. 
Dates of screenings, randomizations, screen failures and study completion, as well as 
randomization codes and data about inclisiran injections administered to the participant will be tracked using an Interactive Response Technology (IRT). The system will b e supplied by a 
vendor, who will also manage the database. The data will be sent electronically to [COMPANY_001] (or a designated CRO) at specific timelines.  
Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked. Any changes to the database after that time can only be made after written agreement by [CONTACT_848503].  
11.3 Site monitoring  
Before study initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001]/UBC representative will review the protocol and data capture requirements (i.e., direct EHR data capture or eCRFs) with the investigators and their staff. Durin g the study, [COMPANY_001]  employs 
several methods of ensuring protocol and GCP compliance and the quality/integrity of the sites’ data. The field monitor will conduct on -site or virtual monitoring visits to check the 
completeness of participant records, the ac curacy of data capture / data entry, the adherence to 
the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Video conferencing, electronic Trial Master File (eTMF) and remote source document review 
technologies will be utilized as needed to ensure that essential monitoring functions are supported when virtual monitoring visits are conducted. Key study personnel must be available to assist the field monitor during these visits.  
Continuous remote monitoring of each site’s data may be performed by a centralized [COMPANY_001]/UBC/CRA organization. Additionally, a central analytics organization may analyze data & identify risks & trends for site operational parameters, and provide reports  to 
[COMPANY_001]  clinical teams to assist with trial oversight.  
The investigator must maintain source documents for each participant in the study, consisting of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on CRFs must be traceable to these source documents in the 
[COMPANY_001]  Confidential  Page 70 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 participant's file.  The investigator must also keep the original informed consent form signed by 
[CONTACT_2299] (a signed copy is given to the participant). 
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency with the data capture and/or data entry. [COMPANY_001]  monitoring standards require full 
verification for the presence of informed consent, adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be used for all primary variables. Additional checks of the consistency of the source data with the CRFs are performed according to the study- specific monitoring plan. No information in source documents about the identity of the 
participants will be disclosed.  
[ADDRESS_1179763] a two -sided alternative 
hypothesis, employing a significance level of 0.05. 
Efficacy, safety, and other data will be summarized. For continuous variables, summary 
statistics (mean, standard deviation, median, 25th and 75th percentiles, interquartile range, 
minimum, and maximum) at each time point and for change from baseline to each time point will be reported by [CONTACT_1570]. For discrete variables, frequency counts and percentages at each time point will be reported by [CONTACT_1570]. 
12.1 Analysis sets  
The Full Analysis Set (FAS) comprises all randomized participants. According to the intent -to-
treat principle, participants will be analyzed according to the treatment group they have been assigned to during the randomization procedure. 
The Per -Protocol Set is a subset of the Full Analysis Set in which participants are not treated 
with any inclisiran if they are randomized to the usual care treatment group or  do not have any 
major protocol deviations (including deviations from inclusion/exclusion criteria) in either 
treatment group.    
The Restricted Set 1 is a subset of the Full Analysis Set which includes only participants without 
changes in background lipid-lowering therapy. 
The Restricted Set 2 is a subset of the Full Analysis Set which includes only participants who 
received three doses of inclisiran in the inclisiran + usual care group (i.e., excludes patients in the inclisiran + usual care group who missed one or more dose s) and all participants in the usual 
care group (including participants who may have used commercially available inclisiran). 
The Safety Set includes all participants who received study treatment. Participants will be 
analyzed according to the study treatment received, where treatment received is defined as the randomized/assigned treatment if the participant took at least one dose of that treatment or the first treatment received if the randomized/assigned treatment was never received.   
[COMPANY_001]  Confidential  Page 71 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 12.2 Participant demographics and other baseline characteristics  
Demographic and other baseline data including disease characteristics will be listed and summarized descriptively by [CONTACT_131369].  
Relevant medical histories and current medical conditions at baseline (i.e., prior to first dose of study treatment) will be summarized by [CONTACT_6657], by [CONTACT_90214].   
12.3 Treatments  
Concomitant medications and significant non- drug therapi[INVESTIGATOR_848486] (ATC) classification system, by [CONTACT_1570], for the Safety Set.  
12.4 Analysis supporting primary objectives  
12.4.1 Definition of primary endpoints 
The primary efficacy variables are the following:  
1. Percent change from baseline in LDL -C  
2. Achieving LDL-C < 70 mg/dL (yes, no) 
The primary analysis time point for both primary efficacy variables is at Day 330.  
12.4.2 Statistical model, hypothesis, and method of analysis 
The primary analysis of primary efficacy variable 1 to address the primary objective will be based on the following estimand: 
• Population: Defined through appropriate inclusion/exclusion criteria to reflect the targeted population 
• Variable: Percent change from baseline in LDL -C [The primary analysis time point is 
at Day 330.] 
• Treatment: Inclisiran + usual care or usual care  
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131336]. This intercurrent event will be ignored in the analysis, as the design of the trial allows for participants in the usual care group to potentially use in clisiran. 2. 
Discontinuation of study treatment.  This intercurrent event will be ignored in the analysis.  
• Summary measure: Least -squares mean difference between inclisiran + usual care 
group and usual care group 
The null hypothesis is that the mean percent change from baseline in LDL -C at Day 330 for 
inclisiran + usual care and usual care treatment groups are equal. The alternative hypothesis is that the mean percent change from baseline in LDL -C at Day 330 for in clisiran + usual care 
treatment group is not equal to that of the usual care treatment group.  
[COMPANY_001]  Confidential  Page 72 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 Primary efficacy variable 1 will be analyzed using mixed- effects model repeated measures 
(MMRM) with treatment, visit, baseline, treatment-by- visit interaction, and baseline -by-visit 
interaction as explanatory variables. An unstructured working correlation matrix will be 
assumed for this model ( Diggle et  al 2002).  Least -squares mean of each treatment group, least -
squares mean treatment difference, two -sided 97.5% confidence interval for the treatment 
difference, and p- value based on the fitted MMRM will be reported for each applicable visit 
(day). If the p -value based on a two- sided test for treatment at Day 330 is < 0.[ADDRESS_1179764] squares mean treatment difference ([inclisiran + usual care] - usual care) is 
less than 0, statistical significance in favor of inclisiran + usual care is shown.  Al l efforts will 
be made to follow up participants until the end of the study.  Participants will be expected to follow the visit schedule and assessments even after discontinuation of study treatment.  Data after participants discontinued study treatment wi ll be used in the analysis (“retrieved dropout”).  
The primary analysis of primary efficacy variable 2 to address the primary objective will be based on the following estimand: 
• Population: Defined through appropriate inclusion/exclusion criteria to reflect the targeted population 
• Variable: Achieving LDL-C < 70 mg/dL (yes, no)  [The primary analysis time point is at Day 330.] 
• Treatment: Inclisiran + usual care or usual care  
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131336]. This intercurrent event will be ignored in the analysis, as the design of the trial allows for participants in the usual care group to potentially use in clisiran. 2. 
Discontinuation of study treatment.  This intercurrent event will be ignored in the analysis.  
• Summary measure: Odds ratio of inclisiran + usual care to usual care for achieving LDL -C < 70 mg/dL 
Let π
j denote the probability of achieving LDL -C < 70 mg/dL at Day 330 for treatment group 
j, j = 0, 1, where 0 corresponds to usual care and 1 corresponds to inclisiran + usual care. Accordingly, π
j/(1 – π j) is the odds for treatment group j, j = 0, 1. 
The following null hypothesis (H 0) will be tested against the alternative hypotheses (H A), 
corresponding to the comparison inclisiran + usual care versus usual care:  
H0: [π 1/(1 – π1)]/[π 0/(1 – π0)] ≤ 1 versus H A: [π 1/(1 – π 1)]/[π 0/(1 – π 0)] > [ADDRESS_1179765] -baseline visit using a logistic 
regression model with treatment and baseline LDL -C as explanatory variables 
(Stokes et  al 2012). The odds ratio, two- sided 97.5% confidence interval for the odds ratio, and 
p-value based on the fitted model will be reported. If the p- value based on a two -sided test for 
inclisiran + usual care versus usual care at Day 330 is < 0.025 and the correspo nding odds ratio 
is greater than 1, statistical significance in favor of inclisiran + usual care is shown.  
The primary analysis of both primary efficacy variables will be based on the Full Analysis Set.  
[COMPANY_001]  Confidential  Page 73 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 12.4.3 Handling of intercurrent events of primary estimand 
The remaining intercurrent event of the primary estimand for the two primary efficacy variables are the following: 1. Potential use of inclisiran by [CONTACT_131336]. This intercurrent event will be ignored in the analysis, as the design of the trial allows for participants in the usual care group to potentially use inclisiran. 2. Discontinuation of study treatment.  This intercurrent event will be ignored in the analysis.  
12.4.[ADDRESS_1179766] LDL -C ≥ 70 mg/dL (i.e., “non- responder”).  
12.4.5 Sensitivity analyses  
The sensitivity analysis of primary efficacy variable 1 to address the primary objective will be 
based on the following estimand: 
• Population: Defined through appropriate inclusion/exclusion criteria to reflect the targeted population 
• Variable: Percent change from baseline in LDL -C [The primary analysis time point is 
at Day 330.] 
• Treatment: Inclisiran + usual care or usual care  
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131336]. This intercurrent event will be ignored in the analysis, as the design of the trial allows for participants in the usual care group to potentially use in clisiran. 2. 
Discontinuation of study treatment.  This intercurrent event will be ignored in the analysis.  
• Summary measure: Probability of observing the same or a more favorable response with inclisiran + usual care relative to usual care  
For the above estimand , primary efficacy variable [ADDRESS_1179767]. The probability of observing the same or 
a more favorable response with inclisiran relative to usual care will be estimated using nonparametric methods, and the associated two -sided 97.5% confidence interval will also be 
reported ( Chen  and Kianifard  2000).  
The sensitivity analysis of primary efficacy variable 2 to address the primary objective will be based on the following estimand: 
• Population: Defined through appropriate inclusion/exclusion criteria to reflect the targeted population 
• Variable: Achieving LDL-C < 70 mg/dL (yes, no) [The primary analysis time point is at Day 330.]   
• Treatment: Inclisiran + usual care or usual care  
[COMPANY_001]  Confidential  Page 74 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 • Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131336]. This intercurrent event will be ignored in the analysis, as the design of the trial allows for participants in the usual care group to potentially use in clisiran. 2. 
Discontinuation of study treatment.  This intercurrent event will be ignored in the analysis.  
• Summary measure: Treatment difference ([inclisiran + usual care] – usual care) in the proportion of participants who achieve LDL-C < 70 mg/dL 
For the above estimand, primary efficacy variable [ADDRESS_1179768] (normal approximation to the binomial 
distribution) to compare inclisiran + usual care versus usual care.  If the treatment comparison 
p-value at Day 330 is < 0.025 and the proportion of participants who achieve LDL -C < 70 
mg/dL is higher in inclisiran + usual care treatment group, statistical significance in favor of inclisiran + usual care is shown. A two -sided 97.5% confidence interval for the difference 
between inclisiran + usual care and usual care in the proportion of participants who achieve LDL -C < 70 mg/dL will be calculated, using the normal approximation to the binomial 
distribution. 
12.4.6 Supplementary analysis 
A supplementary analysis of primary efficacy variable 1 will be based on the following 
estimand:  
• Population: Defined through appropriate inclusion/exclusion criteria to reflect the targeted population 
• Variable: Percent change from baseline in LDL -C [The primary analysis time point is 
at Day 330.]  
• Treatment: Inclisiran + usual care or usual care  
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_848504]. 2. Discontinuation of study treatment.  Data after the occurrence of either one of the above two intercurrent events will be excluded from the analysis (using MMRM).  
• Summary measure: Least -squares mean difference between inclisiran + usual care group 
and usual care group 
Subgroup analyses of the two primary efficacy variables will be performed by [CONTACT_131372] -
lowering therapy at baseline. Other subgroups to be considered will be defined in the Statistical Analysis Plan. 
12.4.7 Supportive analyses  
The primary analysis of the two primary efficacy variables will be repeated for the Per -Protocol 
Set, Restricted Set 1, and Restricted Set 2.  
[COMPANY_001]  Confidential  Page 75 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 12.5 Analysis supporting secondary objectives  
12.5.1 Efficacy and/or Pharmacodynamic endpoint(s)  
The secondary efficacy variables are the following:  
1. Absolute change from baseline in LDL -C 
2. Average percent change from baseline in LDL -C levels to each post- baseline visit  
3. Average absolute change from baseline in LDL- C levels to each post -baseline visit  
4. Achieving LDL -C < 100 mg/dL (yes, no) (among the subset of participants with LDL -
C ≥ 100 mg/dL at baseline)  
5. Achieving ≥ 50% reduction from baseline in LDL -C (yes, no) 
6. Achieving LDL-C < 55 mg/dL (yes, no)  
7. Percent change from baseline in apoB  
8. Absolute change from baseline in apoB  
9. Percent change from baseline in VLDL  
10. Absolute change from baseline in VLDL  
11. Percent change from baseline in non- HDL -C 
12. Absolute change from baseline in non -HDL -C 
13. Percent change from baseline in total cholesterol  
14. Absolute change from baseline in total cholesterol  
15. Percent change from baseline in Lp(a)  
16. Absolute change from baseline in Lp(a)  
17. Percent change from baseline in HDL -C 
18. Absolute change from baseline in HDL -C 
19. Percent change from baseline in triglycerides  
20. Absolute change from baseline in triglycerides  
21. Intensity of lipid -lowering therapy (decrease in dose, no change in dose, increase in 
dose) 
22. Proportion of days covered (total number of days on either statin, ezetimibe, or PCSK9 inhibiting monoclonal antibody therapi[INVESTIGATOR_848487]) 
23. Discontinuation of statin therapy (i.e., no statin use ≥ 30 days before the end-of-study visit) (yes, no) 
Analyses of secondary efficacy variables 1 and 7 - 20 will be similar to the primary analysis of 
primary efficacy variable 1 (using MMRM, but with a two -sided 95% confidence interval for 
the treatment difference).  
[COMPANY_001]  Confidential  Page 76 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 Secondary efficacy variables 2, 3, and [ADDRESS_1179769]-squares mean treatment difference, 95% confidence interval for the  treatment difference, 
and p- value based on the fitted model will be reported.  
Secondary efficacy variables [ADDRESS_1179770] -baseline visit using a 
logistic regression model with treatment and baseline LDL -C as explanatory variables 
(Stokes et  al 2012). The odds ratio, 95% confidence interval for the odds ratio, and p-value 
based on the fitted model will be reported. Missing data will be imputed using “non-responder” (i.e., “negative” outcome) imputation. 
Secondary efficacy variable [ADDRESS_1179771] -baseline visit using a proportional 
odds model with treatment and baseline LDL -C as explanatory variables ( Stokes et  al 2012). 
The odds ratios, 95% confidence intervals for the odds ratios, and p- values based on the fitted 
model will be reported. Missing data will not be imputed.  
Analyses of secondary efficacy variables will be based on the Full Analysis Set.  
12.5.2 Safety endpoints 
For all safety analyses, the Safety Set will be used. All listings and tables will be presented by 
[CONTACT_1570].  
Adverse events  
All information obtained on adverse events will be displayed by [CONTACT_131373].  
The number (and percentage) of participants with treatment- emergent adverse events (events 
started after the first dose of study medication or events present prior to start of double -blind 
treatment but increased in severity based on preferred term) will be summarized in the following 
ways:  
• by [CONTACT_1570], primary system organ class and preferred term. 
• by [CONTACT_1570], primary system organ class, preferred term and maximum 
severity.  
• by [CONTACT_1570], Standardized MedDRA Query (SMQ) and preferred term.  
Separate summaries will be provided for study medication related adverse events, death, serious adverse events, other significant adverse events leading to discontinuation. 
A participant with multiple adverse events within a primary system organ class is only counted 
once towards the total of the primary system organ class.  
Vital signs  
All vital signs data will be listed by [CONTACT_1570], participant, and visit/time and if ranges are available, abnormalities will be flagged. Summary statistics will be provided by [CONTACT_10659]/time.  
Clinical laboratory evaluations  
[COMPANY_001]  Confidential  Page 79 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 For primary efficacy variable 2, i.e., achieving LDL -C < 70 mg/dL (yes, no), a z -test, an 
allocation ratio of 1:1, and a two- sided significance level of 0.025 were used in the calculation 
of sample size. Table 12 -2 considers total sample sizes for several expected proportions of 
participants who achieve LDL -C < 70 mg/dL at Day 330 in the usual care and inclisiran + usual 
care treatment groups, and powers of 0.85 and 0.90 (nQuery Version [IP_ADDRESS]). From Table 12-
2, the expected proportions of 0.55 and 0.75 in the usual care and inclisiran + usual care treatment groups, respectively, and a power of 0.85 were chosen to provide a total sample size of 242 participants. 
Table 12-2 Sample size calculations for achieving LDL-C < 70 mg/dL 
Proportion in usual 
care group  Proportion in inclisiran 
+ usual care group  Power = 0.85  Power = 0.90  
0.50 0.65 464 536 
0.50 0.70 256 294 
0.55 0.70 446 514 
0.55 0.75 242 278 
Based on the sample size calculations in Table 12 -1 and Table 12 -2, a total sample size of 306 
together with a loss to follow -up rate of 20% at Day 330 require approximately 384 participants  
(192 participants per treatment group) to be randomized. This will also allow examination of subgroups with reasonable sample sizes.  
12.8.2 Secondary endpoint(s)  
Not applicable. 
13 Ethical considerations and administrative procedures 
13.1 Regulatory and ethical compliance  
This clinical study was designed and shall be implemented, executed and reported in accordance with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local regulations (including European Directive 2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki. 
13.2 Responsibilities of the investigator and IRB/IEC  
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_30757]/Independent Ethics Committee (IRB/IEC) for the trial protocol, written informed consent form, consent form updates, participa nt recruitment procedures (e.g., 
advertisements) and any other written information to be provided to participants. Prior to study start, the investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] monitors, auditors, [COMPANY_001]  Quality Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site is 
[COMPANY_001]  Confidential  Page 80 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 requested by a regulatory authority, the investigator must inform [COMPANY_001]  immediately that this 
request has been made.  
13.[ADDRESS_1179772]. In addition, after study completion (defined as last patient last visit) and finalization of the study report the results of this trial will be submitted for publication and posted in a publicly accessible database of clinical trial results, such as the [COMPANY_001] clinical trial results website and all required Health Authority websites (e.g., Clinicaltrials.gov, EudraCT etc.) .  
For details on the [COMPANY_001]  publication policy including authorship criteria, please refer to the 
[COMPANY_001]  publication policy training materials that were provided to you at the trial investigator 
meetings.  
13.[ADDRESS_1179773] Quality Management System (QMS) that includes all activities 
involved in quality assurance and quality control, to ensure compliance with written Standard Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines. 
Audits of investigator sites, vendors, and [COMPANY_001]  systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conducted to assess GCP compliance with global and local regulatory requirements, protocols and internal SOPs, and are performed according to written [COMPANY_001] processes. 
[ADDRESS_1179774] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_30830]/IEC and Health Authorities, where required, it cannot be 
implemented.  
[COMPANY_001]  Confidential  Page 81 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 14.[ADDRESS_1179775] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to implementation.  
Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected to take any immediate action required for the safety of any participant  included in this 
study, even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  
[COMPANY_001]  Confidential  Page 82 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 [ADDRESS_1179776]  
Anderson JL, Knowlton KU, May HT, et al (2018) Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease -Real-world experience within a large integrated health 
care system: The IMPRES study. J Clin Lipi[INVESTIGATOR_37487] 12(4):1008-1018.e1. 
Ashwell G, Morell AG (1974) The role of surface carbohydrates in the hepatic recognition 
and transport of circulating glycoproteins. Adv Enzymol Relat Areas Mol Biol 41(0):99-128. 
Atkinson MJ, Kumar R, Cappelleri JC, et al (2005) Hierarchical construct validity of the 
treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health 8( Suppl 1):S9-S24. 
Baigent C, Blackwell L, et al (2010) Efficacy and safety of more intensive lowering of LDL 
cholesterol: a meta -analysis of data from 170,000 participants in 26 randomised trials. Lancet 
376(9753):1670-81. 
Bangalore S, Breazna A, DeMicco DA, et al (2015) Visit -to-visit low -density lipoprotein 
cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial. J Am 
Coll Cardiol 65(15):1539-48. 
Cannon CP, Blazing MA, Giugliano RP, et al (2015) Ezetimibe Added to Statin Therapy after 
Acute Coronary Syndromes. N Engl J Med 372(25):2387- 97. 
Cannon CP, Braunwald E, McCabe CH, et al (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350(15):1495-504. 
Cannon CP, Khan I, Klimchak AC, et al (2017) Simulation of Lipid-Lowering Therapy 
Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2(9):959-966. 
Chan AHY, Horne R, Hankins M, et al (2020) The Medication Adherence Report Scale: A 
measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol 86(7):1281-1288. 
Chen M, Kianifard F (2000) A nonparametric procedure associated with a clinically 
meaningful efficacy measure. Biostatistics 1(3):293 -8. 
Coelho T, Adams D, Conceição I, et al (2020) A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin -mediated (hATTR) 
amyloidosis. Orphanet J Rare Dis 15(1):179. 
Collins R, Reith C, Emberson J, et al (2016) Interpretation of the evidence for the efficacy and 
safety of statin therapy. Lancet 388([ZIP_CODE]):2532-2561. 
Diggle PJ, Heagerty P, Liang KY, et al (2002) Analysis of longitudinal data, 2nd ed; Oxford: 
Oxford University Press. 
Elbashir SM, Harborth J, Lendeckel W, et al (2001) Duplexes of 21- nucleotide RNAs mediate 
RNA interference in cultured mammalian cells. Nature 411(6836):494- 8. 
[COMPANY_001]  Confidential  Page 83 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 Geisbert TW, Hensley LE, Kagan E, et al (2006) Post-exposure protection of guinea pi[INVESTIGATOR_76598] a lethal ebola virus challenge is conferred by [CONTACT_76639]. J Infect Dis 193(12):1650-7. 
Grundy SM, Stone NJ, Bailey AL, et al (2019) 2018 
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of 
Cardiology/American Heart Association Task Force on Clinical Pra ctice Guidelines. 
Circulation 139(25):e1082-e1143. 
Horne R, Weinman J (2002) Self-regulation and self-management in asthma: exploring the 
role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 17(1):17-32. 
Khunti K, Danese MD, Kutikova L, et al (2018) Association of a Combined Measure of 
Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. JAMA Netw Open 1(8):e185554. 
Koskinas KC, Windecker S, Pedrazzini G, et al (2019) Evolocumab for Early Reduction of 
LDL  Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). J Am 
Coll Cardiol 74(20):2452-2462. 
Lambert -Kerzner A, Havranek EP, Plomondon ME, et al (2015) Perspectives of patients on 
factors relating to adherence to post- acute coronary syndrome medical regimens. Patient 
Prefer Adherence 9:1053-9. Mills EJ, O'Regan C, Eyawo O, et al (2011) Intensive statin therapy compared with moderate 
dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J 11:1409- 15. 
Morrissey DV, Blanchard K, Shaw L, et al (2005) Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41(6):1349-56. 
Nishikido T, Ray KK (2018) Inclisiran for the treatment of dyslipi[INVESTIGATOR_035]. Expert Opin 
Investig Drugs 27(3):287-294. 
Ray KK, Landmesser U, Leiter LA, et al (2017) Inclisiran in Patients at High Cardiovascular 
Risk with Elevated LDL Cholesterol. N Engl J Med 376(15):1430-1440. 
Ray KK, Wright RS, Kallend D, et al (2020) Two Phase 3 Trials of Inclisiran in Patients with 
Elevated LDL Cholesterol. N Engl J Med 382(16):1507-1519. 
Rosenblit PD (2019) Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for 
Patients at "Extreme" ASCVD Risk. Curr Diab Rep 19(12):146. 
Sabatine MS, Giugliano RP, Keech AC, et al (2017) Evolocumab and Clinical Outcomes in 
Patients with Cardiovascular Disease. N Engl J Med 376(18):1713-1722. 
Sampson HA, Munoz-Furlong A, Bock SA, et al (2005) Symposium on the definition and 
management of anaphylaxis: summary report. J Allergy Clin Immunol 115(3):584-91. 
[COMPANY_001]  Confidential  Page 84 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 Sampson HA, Munoz-Furlong A, Campbell RL, et al (2006) Second symposium on the definition and management of anaphylaxis: summary report --Second National Institute of 
Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 117:391-7. 
Schwartz GG, Steg PG, Szarek M, et al (2018) Alirocumab and Cardiovascular Outcomes 
after Acute Coronary Syndrome. N Engl J Med 379(22):2097-2107. 
Soutschek J, Akinc A, Bramlage B, et al (2004) Therapeutic silencing of an endogenous gene 
by [CONTACT_76640]. Nature 432(7014):173- 8. 
Stokes ME, Davis CS, Koch GG (2012) Categorical data analysis using the SAS system. 3rd ed; Cary, NC: SAS Institute, Inc.  
Tabernero J, Shapi[INVESTIGATOR_76604], LoRusso PM, et al (2013) First- in-humans trial of an RNA 
interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3(4):406-17. 
Wilson PWF, Polonsky TS, Miedema MD, et al (2019) Systematic Review for the 2018 
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Prac tice Guidelines. 
Circulation 139(25):e1144-e1161. 
Zimmermann TS, Lee AC, Akinc A, et al (2006) RNAi-mediated gene silencing in non-
human primates. Nature 441(7089):111-4. 
[COMPANY_001]  Confidential  Page 85 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 16 Appendices  
16.1 Appendix 1: Clinically notable laboratory values and vital signs  
Vital signs range deviations are defined in Table 16-1: 
Table 16-1 Clinically notable vital signs 
Vital sign  Notable abnormalities  
Pulse (beats/min)  either ≥120 + increase ≥25* or > 130either ≤50 + decrease 
≥30* or < 40  
BP (mmHg)  
* Refers to post -BL value as compared to BL value  
Notable laboratory values are defined in  Table 16 -2: 
Table 16-2 Clinically notable laboratory abnormalities for selected tests 
Parameters  Criteria  
Hematology  
Hemoglobin  ≤ 10 g/dL  
Hematocrit  ≤ 0.8 × LLN  
WBC (total)  ≤ 2.8 ×103 / μL, ≥ 16 ×103 / μL 
Platelet count  ≤ 75 ×103 / μL, ≥ 700 ×103 / μL 
HbA1c  ≥ 6.5% and ≥0.5% change from baseline  
Clinically chemistry  
Creatinine  > 2 mg/dL  
CK > 1 and ≤ 3 × ULN  
CK > 3 and ≤ 5 × ULN  
CK > 5 and ≤ 10 × ULN  
CK > 10 × ULN  
ALT > 1 and ≤ 3 × ULN  
ALT > 3 and ≤ 5 × ULN  
ALT > 5 × ULN  
AST > 1 and ≤ 3 × ULN  
AST > 3 and ≤ 5 × ULN  
AST > 5 × ULN  
Total bilirubin (TBL)  > 2 × ULN  
ALP > 2 × ULN  

[COMPANY_001]  Confidential  Page 86 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 16.2 Appendix 2: Liver event and laboratory trigger definitions & 
follow -up requirements  
Table 16-3 Liver event and laboratory trigger definitions 
  Definition/ threshold  
Liver laboratory triggers  
If ALT, AST and total bilirubin normal at 
baseline:  • ALT or AST > 5 × ULN  
• ALP > 2 × ULN (in the absence of known 
bone pathology)  
• Total bilirubin > 3 × ULN (in the absence of known Gilbert syndrome)
 
• ALT or AST > 3 × ULN and INR > 1.5  
• Potential Hy’s Law cases (defined as ALT or AST > 3 × ULN and Total bilirubin > 2 × ULN 
[mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)
 
• Any clinical event of jaundice (or equivalent 
term)  
• ALT or AST > 3 × ULN accompanied by 
(general) malaise, fatigue, abdominal pain, 
nausea, or vomiting, or rash with 
eosinophilia  
• Any adverse event potentially indicative of a 
liver toxicity*  
If ALT or AST abnormal at baseline:  • ALT or AST > 2x baseline or > 300 U/L 
(whichever occurs first)  
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage-related conditions; non- infectious hepatitis; benign, malignant and unspecified liver neoplasms ULN: 
upper limit of normal  
Table 16-[ADDRESS_1179777] increase without bilirubin increase:    
If normal at baseline:  
ALT or AST > [ADDRESS_1179778]  Normal  
For patients with 
Gilbert’s syndrome: No 
change in baseline 
TBL 
None • No change to study treatment
 
• Measure ALT, 
AST, ALP, GGT, 
TBL, direct and 
indirect bilirubin,  PT/INR, 
albumin, CK, and GLDH in 48 -72 
hours.
 
• Follow -up for 
symptoms.   
If elevated at 
baseline:  
ALT or AST > 2 x baseline  
or > 300 U/L (whichever occurs ﬁrst) 
[COMPANY_001]  Confidential  Page 87 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 ALT or AST  TBL Liver Symptoms  Action  
If normal at baseline:  
ALT or AST > [ADDRESS_1179779] 
for more than two 
weeks  Normal  
For patients with Gilbert’s syndrome: No 
change in baseline 
TBL 
None 
• Interrupt study 
drug 
• Measure ALT, AST, ALP, GGT, TBL, direct and 
indirect 
bilirubin,  PT/INR, 
albumin, CK, and 
GLDH in 48 -72 
hours.
 
• Follow -up for 
symptoms.  
• Initiate close 
monitoring and 
workup for 
competing etiologies.
 
• Study drug can be restarted only if another etiology is 
identiﬁed and liver 
enzymes return to baseline.
 If elevated at 
baseline:  
ALT or AST > 3 x baseline  
or > 300 U/L (whichever occurs 
ﬁrst) for more than two 
weeks  
If normal at baseline:  
ALT or AST > [ADDRESS_1179780] increase with bilirubin increase:  
If normal at baseline:  
ALT or AST > [ADDRESS_1179781]  TBL > [ADDRESS_1179782] (or INR 
> 1.5)  
For patients with Gilbert’s syndrome: 
Doubling of direct 
bilirubin  None If elevated at baseline:  
ALT or AST > 2 x baseline  
or > 300 U/L 
(whichever occurs 
ﬁrst) 
If normal at baseline:  
ALT or AST > [ADDRESS_1179783]  
Normal or elevated  Severe fatigue, 
nausea, vomiting, right upper quadrant pain  If elevated at baseline:  
ALT or AST > 2 x baseline  
or > 300 U/L 
(whichever occurs 
ﬁrst) 
Table 16-5 Follow up requirements for liver laboratory triggers  
Criteria  Actions required  Follow -up monitoring  
Total Bilirubin (isolated)      
>1.5 – 3.[ADDRESS_1179784]  • Maintain treatment  
• Repeat LFTs within 48 -72 
hours  Monitor LFTs weekly until resolution
a to ≤ Grade 1 or to 
baseline  
> 3 - 10 × ULN (in the absence 
of known Gilbert syndrome)  • Interrupt treatment  
• Repeat LFT within 48 -72 
hours  Monitor LFTs weekly until resolution
a to ≤ Grade 1 or to 
baseline (ALT, AST, total 
bilirubin, Albumin, PT/INR, ALP 
and GGT)  
[COMPANY_001]  Confidential  Page 88 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 Criteria  Actions required  Follow -up monitoring  
• Hospi[INVESTIGATOR_6547]  
• Establish causality  
• Record the AE and contributing factors (e.g., 
conmeds, med hx, lab) in 
the appropriate CRF  Test for hemolysis (e.g., reticulocytes, haptoglobin, 
unconjugated [indirect] bilirubin)  
> [ADDRESS_1179785]  • Discontinue the study 
treatment immediately  
• Hospi[INVESTIGATOR_6548]  
• Establish causality  
• Record the AE and contributing factors(e.g., 
conmeds, med hx, lab) in 
the appropriate CRF  ALT, AST, total bilirubin, 
Albumin, PT/INR, ALP and 
GGT until resolutionc 
(frequency at investigator 
discretion)  
Any AE potentially indicative of a liver toxicity*  • Consider study treatment 
interruption or discontinuation
 
• Hospi[INVESTIGATOR_6549]
 
• Establish causality  
• Record the AE and contributing factors(e.g., conmeds, med hx, lab) in 
the appropriate CRF  Investigator discretion  
aResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level 
after a maximum of 6 months, (4) liver transplantation,  and (5) death.  
Based on investigator’s discretion investigation(s) for contributing factors for the liver event can include: Serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent  diseases, history of 
concomitant drug use, exclusion of underlying liver disease. 
[COMPANY_001]  Confidential  Page 89 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 16.3 Appendix 3: Specific Renal Alert Criteria and Actions and Event 
Follow -up 
  
Table 16-6 Specific renal alert criteria and actions 
Renal event  Actions  
Confirmed serum creatinine (sCr) increase 25 – 
49% Consider causes and possible interventions  
Follow up within 2 -5 days  
Serum creatinine increase ≥ 50% + + OR if <18 
years old, eGFR ≤ 35 mL/min/1.73 m2 + Consider causes and possible interventions  
Repeat assessment within 24- 48h if possible  
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected  
Consider participant hospi[INVESTIGATOR_201038] ≥ 3+  
OR 
Protein -creatinine ratio (PCR) ≥ 1g/g Cr (or 
mg/mmol equivalent as converted by [CONTACT_131375])  Consider causes and possible interventions  
Assess serum albumin & serum total protein  
Repeat assessment to confirm  
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected  
New onset hematuria ≥ 3+ on urine dipstick  Repeat assessment to confirm  
Distinguish hemoglobinuria from hematuria  
Urine sediment microscopy  
Assess sCr  
Exclude infection, trauma, bleeding from the 
distal urinary tract/bladder, menstruation  
Consider bleeding disorder  
+ Corresponds to KDIGO (Kidney Disease: Improving Global Outcomes) criteria for Acute Kidney 
Injury  
Additional specialized assessments are available to assess renal function or renal pathology. (Note: In exceptional cases, when a nephrologist considers a renal biopsy, it is recommended 
to make slide specimen available for evaluation by [CONTACT_188664] -wide 
patterns of nephrotoxicity .) 
Whenever a renal event is identified, a detailed patient history and examination are indicated to identify and potentially eliminate risk factors that may have initiated or contributed to the event: 
• Blood pressure assessment (after [ADDRESS_1179786], with an appropriate cuff size)  
• Signs and symptoms like fever, headache, shortness of breath, back or abdominal pain, 
dysuria or hematuria, dependent or periorbital edema  
• Changes in blood pressure, body weight, fluid intake, voiding pattern, or urine output 
• Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic 
failure, contrast media or other known nephrotoxin administration, or other diseases or causes, e.g., dehydration due to delirium, tumor lysis   
[COMPANY_001]  Confidential  Page 90 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 Table 16-[ADDRESS_1179787] in appropriate eCRF(s):  
Urine dipstick and sediment microscopy evidence of drug -induced nephrotoxicity (DIN): crystals, red 
blood cells (dysmorphic/glomerular vs. non- dysmorphic/non- glomerular), white blood cells, tubular 
epi[INVESTIGATOR_526897], BUN, electrolytes (sodium, potassium, phosphate, calcium), bicarbonate and uric 
acid 
Urine output  
Review and record possible contributing factors to the renal event (co- medications, other co -morbid 
conditions) and additional diagnostic procedures (MRI etc.) in the appropriate eCRF(s)  
Monitor participant regularly (frequency at investigator’s discretion) until – 
- Event resolution: (sCr within 10% of baseline or PCR < 1 g/g Cr, or albumin-to -creatinine ratio 
(ACR) <300 mg/g Cr)  
or 
- Event stabilization: sCr level with ±10% variability over last 6 months or protein- creatinine ratio 
stabilization at a new level with ±50% variability over last 6 months.  
- Analysis of urine markers in samples collected over the course of the DIN event  
ACR (Albumin -to-creatinine ratio), DIN (Drug- Induced Nephrotoxicity), PCR (Protein- creatinine ratio), 
MRI (Magnetic Resonance Imaging), sCR (serum creatinine)  
  
  
[COMPANY_001]  Confidential  Page 91 of 94 
Amended Clinical Trial Protocol (v04 Clean)  Protocol No. CKJX839A1US01  
 
 
 16.4 Appendix 4: Sampson Criteria for Diagnosing Anaphylaxis  
Anaphylaxis is highly likely when any one of the following three criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) 
AND AT LEAST ONE OF THE FOLLOWING:  
a. Respi[INVESTIGATOR_7798] (e.g., dyspnea, wheeze-bronchospasm, stridor, reduced peak 
expi[INVESTIGATOR_10229] [PEF], hypoxemia) 
b. Reduced blood pressure or associated symptoms of end-organ dysfunction (e.g., hypotonia 
[collapse], syncope, incontinence) 
2. Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for that 
patient (minutes to several hours):  
a. Involvement of the skin- mucosal tissue (e.g., generalized hives, itch -flush, swollen lips-
tongue-uvula) 
b. Respi[INVESTIGATOR_7798] (e.g., dyspnea, wheeze, bronchospasm, stridor, reduced PEF, hypoxemia 
c. Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope, incontinence) 
d. Persistent gastrointestinal symptoms (e.g., painful abdominal cramps, vomiting)  
3. Reduced blood pressure after exposure to a known allergen for that patient (minutes to several hours): 
a. Adults: systolic blood pressure <90 mmHg or >30% decrease from that person’s baseline 
Source: Sampson et  al 2005 and Sampson et  al 2006 
 
  